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II. Resumo	  
De acordo com as estatísticas da Organização Mundial de Saúde, o cancro é a segunda 
causa de morte em todo o mundo, provocando 7,565 milhões de mortes por ano [1].  
 As últimas décadas têm sido férteis no aparecimento de novos tratamentos para o cancro, 
muito devido aos nefastos efeitos secundários que os tratamentos tradicionais infligem aos 
doentes. Muitos desses avanços têm sido possibilitados pelo crescente conhecimento dos 
processos fisiopatológicos e bioquímicos característicos do aparecimento e desenvolvimento 
do cancro. O processo de permeabilidade e retenção aumentadas (PRA) (do inglês “Enhanced 
Permeability and Retention”- EPR) é um dos poucos processos característico dos tumores 
sólidos que impulsionou o desenvolvimento de uma nova abordagem no campo da 
quimioterapia. A teoria do PRA postula que a captação e acumulação de macromoléculas 
biocompatíveis está aumentada nos tumores, muito devido ao desenvolvimento deficiente da 
sua vasculatura e sistema linfático e da síntese aumentada de mediadores de permeabilidade 
[2]. A albumina é uma das referidas macromoléculas que são preferencialmente acumuladas 
nos interstícios dos tumores e no interior das suas células. Esta proteína encontra-se em 
maioria na porção proteica do plasma sanguíneo, perfazendo um total de cerca 50-70% das 
proteínas em suspensão no plasma e apresentando um período semi-vida de cerca de 19 dias. A 
albumina, que pode ser degradada intracelularmente, torna-se então numa fonte de azoto e 
energia para as células tumorais, que têm necessidade aumentada de energia e nutrientes 
devido à sua divisão desregulada. A albumina começa por transpor as paredes dos vasos por 
transcitose mediada pela proteína gp60 que se encontra à superfície de algumas células 
epiteliais [3]. Quando se encontra na proximidade de células tumorais há um reconhecimento 
da albumina por proteínas membranares e a proteína é endocitada e subsequentemente 
degradada no interior de lisossomas.  A albumina liga-se a uma grande variedade de ligandos 
endógenos tal como ácidos gordos não-esterificados e a bilirrubina em múltiplos locais da sua 
estrutura. Algumas substâncias activas comuns são também ligadas à albumina em condições 
fisiológicas, tal como o ibuprofeno, diazepam, varfarina e o 5-fluorouracilo (5-FU) [4][5]. No 
que diz respeito à ligação do 5-FU à albumina, esta foi descrita como sendo de baixas 
afinidade e especificidade em comparação com outras substâncias tais como o diazepam.  
 O 5-FU é uma droga utilizada no tratamento de cancro, nomeadamente da mama e 
cólon, e está em prescrição clínica há mais de 50 anos [6]. Esta substância análoga das 
pirimidinas tem-se afirmado como uma droga antineoplásica relativamente bem sucedida. No 
entanto o rácio entre a dose eficaz e a dose tóxica é pequeno, ou seja, uma resposta terapêutica 
adequada é pouco provável sem alguma toxicidade. É frequente a ocorrência de episódios 
mucosite, mielossupressão, diarreia e neurotoxicidade entre os doentes submetidos a regime de 
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quimioterapia com 5-FU. Sendo uma molécula de pequenas dimensões, é rapidamente 
distribuída pelos tecidos corporais e catabolizada pelo fígado, que a inactiva através da redução 
do anel pirimidínico. O 5-FU é assim rapidamente eliminado pelo corpo, apresentado um 
período de semi-vida em circulação entre 10 e 20 minutos [5]. Devido a esta rápida eliminação, 
o efeito terapêutico do 5-FU é condicionado pelo que seria desejável conseguir implementar 
uma estratégia para prolongar o tempo desta substância na circulação sanguínea. Neste sentido 
há já várias abordagens registadas, nomeadamente através da síntese de partículas onde o 5-FU 
é incorporado num transportador proteico ou polimérico. Desta forma podem ainda ser 
exploradas características como a libertação controlada do princípio activo ou até uma 
conjugação de substâncias ligadas a um veículo [7].   
 Tada et al [8] descreveu a síntese de 5-fluorouracil-ácido-acético (FUAc) numa 
tentativa de melhorar as capacidade antineoplásicas do 5-FU. No entanto não existem no artigo 
quaisquer referências a testes de citotoxicidade à referida substância. Mais tarde um grupo 
coreano utilizou um conjugado de FUAc ligado a albumina humana e testou a suas 
propriedades farmacocinéticas em soluções fisiológicas, no entanto não há referências quanto 
ao método de síntese nem ao rácio de moléculas de FUAc por moléculas de albumina [9]. Os 
resultados descritos por este grupo sugerem que a ligação FUAc-albumina é bastante estável 
uma vez que a libertação de 5-FU do conjugado se limita a cerca de 1% numa solução 
fisiológica de pH 9. Do ano seguinte, 1990, data uma outra publicação de um grupo coreano 
referente ao conjugado FUAc-albumina humana, desta vez por Chung et al [10]. Mais uma vez 
não está descrito o protocolo de síntese, no entanto os resultados obtidos dos testes em coelhos 
revelaram-se promissores. O conjugado manteve a concentração de 1µg/ml de 5-FU no sangue 
durante um período de 3 a 24 horas e apenas 5-FU foi libertado das partículas de FUAc-
albumina humana, não FUAc. O 5-FU ter-se-á libertado das partículas de FUAc-albumina por 
um processo ainda desconhecido. Os coelhos receberam uma infusão de suspensão da partícula 
durante 30 minutos. Foi também descrita a presença de 5-FU no tecido cerebral após a 
administração de FUAc-albumina humana, ao contrário do que aconteceu com infusões de 5-
FU e FUAc.  
 Tendo por base as publicações acima referidas, Koziol et al [11] publicou o protocolo 
de síntese de um conjugado de FUAc-albumina bovina e ainda a caracterização da mesma 
partícula e testes de citotoxicidade in vitro. A reacção de síntese da partícula de FUAc foi 
adaptada de Tada et al [8]. De forma a criar uma ligação covalente entre a molécula proteica, 
neste caso a albumina bovina, e a de FUAc foi utilizado o método EDC/NHS com algumas 
adaptações [12]. Este método de cross-linking cria uma ligação covalente entre o grupo 
carboxilo da molécula de FUAc e os grupos ε-amina livres nas extremidades das cadeias 
laterais das lisinas. O sucesso da síntese foi confirmado por ionização-dessorção com laser 
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assistida por matriz – tempo de voo (MALDI-TOF), havendo uma média de 12 moléculas de 
FUAc por albumina. De forma a testar a citotoxicidade do conjugado foram selecionadas duas 
linhas celulares isoladas de carcinoma mamário, MDA-MB-231 e T-47D. Estas duas linhas 
celulares diferem entre si na expressão de uma proteína de membrana (mABP - plasma-
membrane albumin-binding protein) identificada como influente no uptake de uma partícula, já 
em uso clínico, de paclitaxel conjugado com albumina [13], sendo que as células da linhas T-
47D expressam esta proteína e as MDA-MB-231 não. Foi encontrada uma relação entre a 
presença desta proteína e a inibição das células uma vez que o efeito exercido pela partícula de 
FUAc-BSA e 5-FU mostrou-se similar.  
 Para o projecto sobre o qual assenta esta tese foram escolhidas três linhas celulares 
isoladas de carcinoma da mama: MDA-MB-231, T-47D e MCF-7. A terceira linha celular 
referida expressa a proteína anteriormente referida, mABP, e ainda uma outra também descrita 
como influente no uptake de nab-paclitaxel, a SPARC (de secreted protein, acidic and rich in 
cysteine).  
 A síntese do da partícula conjugada foi realizada de acordo com o protocolo descrito 
por Koziol et al substituindoa albumina bovina por albumina humana (albumina sérica humana 
– ASH). O sucesso da síntese foi confirmado por MALDI-TOF e foi obtida uma média de 15 
moléculas de FUAc por ASH. A conformação da proteína foi analisada por espectroscopia de 
dicroísmo circular, o que revelou que a estrutura da proteína sofreu apenas alterações pouco 
consideráveis quando comparável com a albumina antes da reacção de ligação. De forma a 
testar a capacidade de inibição que a partícula de FUAc-ASH tem sobre as células, estas foram 
incubadas durante um período máximo de 96 horas com 6 concentrações diferentes da 
partícula no meio de cultura celular, assim como das outras substâncias puras (FUAc, ASH e 
5-FU), de forma a ser possível estabelecer uma comparação. A avaliação do poder de inibição 
das substâncias sobre as células foi avaliado através do teste de viabilidade celular MTT e 
posteriormente confirmado através de contagem celular com azul de tripano. Foram incubadas 
células nas mesmas condições e período de tempo, sem adição de nenhuma das substâncias a 
testar como controlo. A inibição registada devido ao FUAc-ASH foi menos pronunciada que a 
obtida pela administração de 5-FU, no entanto foi clara a inibição exercida tanto pela partícula 
de FUAc-ASH como pela molécula de FUAc. Tal como seria de esperar, foi o 5-FU o 
composto que causou uma inibição do metabolismo celular mais acentuada. Pelos resultados 
obtidos não foi possível destacar a importância das proteínas mABP e SPARC no uptake das 
partículas de FUAc-ASH. No entanto é de salientar que este efeito é sugerido pelos resultados 
obtidos após 96 horas de incubação, onde as células da linha MCF-7 apresentam uma maior 
inibição comparativamente às restantes. Esta linha celular apresenta um período de duplicação 
mais longo do que as restantes duas linhas celulares, portanto é plausível supor que o 
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prolongamento do período de incubação com as substâncias a testar produza resultados mais 
significativos para uma clarificação da importância das referidas proteínas membranares no 
uptake do FUAc-ASH. É também de considerar que existem diferenças estruturais entre as 
albuminas humana e bovina, sendo que a bovina tem vindo a ser descrita na literatura como 
mais estável. Este facto pode também influenciar a libertação do 5-FU do conjugado, 
apresentando assim mais uma razão para a necessidade de uma período de incubação mais 
prolongado.   
 Os resultados obtidos sugerem que o conjugado FUAc-ASH possui características 
passíveis de uma aplicação clínica, no entanto estes devem ser considerados como preliminares 
e será necessário uma posterior confirmação do potencial da partícula. A confirmar-se que a 
partícula de FUAc-ASH actua por meios semelhantes a outros conjugados de albumina já no 
mercado (Abraxane, por exemplo), esta abordagem poderá representar um avanço significativo 
no tratamento de cancros susceptíveis à acção do 5-FU.  
 
Palavras-chave: Cancro, micro-transportador, drug targeting, albumina, 5-
Fluorouracilo, 5-Fluorouracilo-ácido acético, 5-Fluorouracilo-ácido acético – Albumina sérica 
humana 
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III. Abstract	  
 
Nowadays, cancer is one of the major death causes worldwide (7.565 million deaths 
per year according to WHO statistics). Besides the registered developments in cancer 
treatments, what leads to improved clinical results; the side effects suffered by the patients are 
still very hard to bear with mainly referring to chemotherapy. In order to reduce these side 
effects, one of the explored approaches was to link the chemotherapy drug to a carrier suitable 
to keep the cytotoxic agent in the circulating blood for a longer period and to minify the drug 
toxicity for the healthy cells.  
Within this drug carrier approach, human serum albumin was chosen as a suitable 
carrier and for the active substance the choice fell on one adduct of 5-fluorouracil. 5-
Fluorouracil is in clinical usage for many years, mainly for treatment of solid cancers (breast 
and colon cancer) and, as most of the chemotherapy drugs, its toxicity limits the tolerable 
administered dosage for treatment. In previous works results showed that the coupling of 
cytostatic drugs to blood proteins could represent an advantage because it reduces the toxicity 
and is able to keep the cytostatic action. 
To synthesize this adduct, named 5-fluorouracil acetic acid (FUAc), an acetic acid side 
chain was introduce at one of the nitrogen atoms in the » ring. With the attachment of this side 
chain, 5-FU acquired the ability to bind to the free amine groups of HSA. 
 An average of 15 FUAc molecules were bound to one HSA. The particle conformation 
was assessed by Circular dichroism (CD) spectroscopy and minimal differences were 
registered between the spectra of pure HSA and FUAc-HSA, suggesting that the coupling 
procedure had not induced major structure alterations.  
 Three breast cancer cell lines (MDA-MB-231, T-47D and MCF-7) were chosen for the 
evaluation of the active agents cytotoxicity. These cell lines were chosen mainly due to their 
difference in mABP and SPARC proteins expression, reported to have a central role in albumin 
uptake by the cells. MDA-MB-231 cells do not express these proteins, T-47D is positive for 
mABP and MCF-7 express both the proteins.  
Cells were incubated with the four compounds – HSA, FUAc-HSA, FUAc and 5-FU- 
for periods of 24, 48, 72 and 96 hours. For each compound six different concentrations were 
taken, from 1 to 500µM. At every 24 hours a MTT assay was performed to assess the 
inhibition of cell metabolism.  
The three cell lines tested were inhibited by 5-FU, FUAc and FUAc-HSA but none of 
them registered inhibition related to HSA. MCF-7 cell line was the one registering a highest 
Abstract 
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metabolism inhibition at 96 hours when incubated with FUAc-HSA. In the previous time 
points, T-47D cell line registered a higher inhibition when compared with the other cell lines. 
5-FU was the substance causing the highest in all cell lines. Regarding to FUAc, MDA-MB-
231 cell line was the one showing the highest inhibition. 
 FUAc-HSA might have advantages upon 5-FU for treating solid cancers although 
further tests should be performed. The dependence on SPARC for FUAc-HSA uptake by the 
cells was not clear however metabolism inhibition of MCF-7 cells at 96 hours suggested the 
relation between this protein and enhanced uptake to be valid.  
Keywords: Cancer, microcarrier, drug targeting, Albumin, 5-Fluorouracil, 5-
Fluorouracil-acetic acid, FUAc-HSA 
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1. Introduction	  
In the first part of this work a literature review will be presented in order to enframe it 
theoretically. Through the following chapter the material and methods are listed and explained. 
On the third chapter the results can be found and, finally, the last chapter regards the 
discussion of all the procedures and results.    
	  
1.1 Cancer	  
Back in the ancient Egypt people already suffered from cancer and physical proofs 
survived until nowadays, together with fossilized bone tumors in mummies. Written references 
to cancer, even still not using this word that would appear later, could be found in manuscripts 
dated from 3000 BC.  
From these ancient times to nowadays, numerous improvements in cancer treatment 
had hopefully been done. Ancient Egyptians classified cancer as having no possible treatment 
back then, although they described the procedure to remove breast tumors by cauterization 
with an instrument called fire drill. Scientific evolution made possible to currently have 
treatments as sophisticated as targeting genetic alterations characteristics of tumors [14]. 
One of the most remarkable scientific discoveries on the cancer subject was the ability 
of healthy body cells to go through all the steps from normal dividing and metabolic activity to 
fast out of control dividing. Several studies 
have suggested that tumorigenesis is a result of 
progressive genetic alterations of normal human 
cells, leading in last instance to highly 
malignant derivatives. The human is composed 
of both dividing and no dividing cells. Highly 
specialized and differentiated cells like neurons, 
for instance, are able to keep their functions 
without dividing, however other cells like 
epithelial and bone marrow need to replicate to 
maintain their function. The balance is naturally 
maintained in the whole body by controlling the 
dividing process and death of cells, but when 
this balance process fails this can happen to be the starting point of a tumor. Every cell has an 
intern clock governing its division activity and oncogenes modify it by exerting pressure for 
the cell to go further on the dividing process. This pressure works at one of the gap phases 
Figure  1:   Cell   cycle   control   by   tumour   suppressor  and   oncogenes[15].   The   red   bars   represent  checking  points   that   the   tumours   suppressors   are  to  maintain  and  oncogenes  try  to  overcome.  
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(either G1 or G2), at S phase or mitosis. Oncogenes are believed to be capable of rescuing cells 
from programed cell death as well [15]. Even considering that most types of cancers 
experience different processes to achieve their capabilities, ultimately they all acquire the 
following characteristics: -­‐ Low	  sensitivity	  to	  anti-­‐growth	  signals	  -­‐ Sustained	  angiogenesis	  -­‐ Unlimited	  replicative	  potential	  -­‐ Tissue	  invasion	  -­‐ Autonomy	  in	  growth	  signals	  -­‐ Apoptosis	  avoidance	  -­‐ Changes	  in	  cell	  metabolism	  
The invasion of other tissues by cancer cells, the so called metastasis, were described as 
responsible for 90% of the deaths in oncologic patients [16].  According to the World Health 
Organization, cancer was responsible for close to 7,6 million deaths in 2008 and predictions 
for future are far from encouraging: 13,1 million for 2030. Statistically, only heart diseases are 
more mortal than cancer [17].  
Great advances on cancer treatment had been possible due to growing knowledge accessible 
nowadays related to tumor pathophysiology. One process considered almost like the ‘holy 
grail’ for cancer drug delivery research is the Enhanced Permeability and Retention, commonly 
known as EPR. The referred designation is due to abnormal characteristics of mostly solid 
tumors, like extensive angiogenesis, what generates hypervasculature, defective vascular 
architecture, impaired lymphatic drainage and an accentuated increased production of some 
permeability mediators, as well as an augmented retention of lipid and macromolecular agents 
(for instance, plasma proteins [18]). The referred overdevelopments occur as a way of 
providing enough oxygen and nutrients to suppress the tumor demanding needs [2]. There is a 
large body of evidence demonstrating that tumors in animals and humans have a great need of 
transferrin and albumin to cover their high demand for iron (III) and amino acids due to their 
fast grew rate [19]. This high demanding need of nutrients and protein entrapment is suggested 
to lead to cachexia, a common condition in tumor patients [18].  
As the normal cells, tumor cells also need oxygen to survive and proliferate, however, due 
to the inefficient vasculature; solid tumors frequently experience a lack of oxygen in some 
locations not close enough to the blood vessels. Oxygenated zones in tumors are that within a 
distance of about 80pm from a blood vessel and the average tumor cell to capillary distance 
was reported as being from 33 to 63pm. Plasma proteins, like albumin, reach and accumulate 
in these tumor regions. After the albumin uptake by cells, the first step for its degradation takes 
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place in the lysosomes by proteases. The product of this degradation is a stock of free amino 
acids in the cytosol, which will be used by the cell for further synthesis of proteins necessary 
for the fast division of cancer cells and also as extra fuel for the Krebs cycle [18], [20].   
Cancer cells in hypoxic areas survive mainly by getting energy from anaerobic glycolysis. 
As protein nutrients are not able to reach these cells as well, only low molecular weight 
substrates like glucose and free amino acids are the only energy sources available for theses 
cells [18].  
The EPR effect can be observed in almost all tumor types, excepting hypovascular tumors 
like prostate and pancreatic [21]. The EPR effect with macromolecular drugs or particles like 
plasma proteins (for example HSA) is a different process from the passive targeting of drugs to 
tumors. Drug retention in tumors with a registered EPR effect is more than days to weeks 
contrasting with retention associated with passive targeting reported as being no more than ten 
minutes [22]. EPR effect can be considered as an advantageous process for cancer drug 
targeting, however some considerations have to be done since every tumor is different and 
even in the same tumor huge differences can be registered. Lammers et al [23] reported 
differences with regard to vascular permeability inside the same tumor, where at a certain part 
particles with 200nm were able to extravasate and in other parts particles with about the size of 
albumin (3-4nm) were not able to enter the interstitium.  
Dreher et al [24] investigated the vascular permeability by dextran molecules varying the 
particles molecular weight and consequently its size. Tumor accumulation was maximal for 
particles between 40 and 70 kDa however particles of 3,3 and 10kDa penetrated deeply and 
homogeneously in the tumor. Therefore, it can be assumed that the size of the particle 
influences the accumulated quantity and how deep it penetrates in the tumor.  
Stehle et al [18] reported that macromolecules reach the tumor vasculature by blood 
convection and after the extravasation to the interstitium of the tumor, by diffusion. The 
movement by diffusion depends on the molecular weight and by comparing igG (150000 Da) 
and albumin (66438 Da) diffusion, albumin diffuses around 10 times faster.  
 
1.2 Cancer	  treatments	  
Cancer is considered one of the biggest health issues, mainly in developed countries as 
it was already referred in the previous chapter. Many studies had been performed in order to 
reach significative improvement in treatments, however, besides recent developments in 
technologies like drug delivery, radiation and chemo therapies, surgery is still pointed as the 
most effective technique for solid cancers. When used as a single treatment, surgery cures 
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more patients than any other individual form of cancer therapy since it is assured that 100% of 
the excised cells are killed, what introduces in most cases a big shrinkage in tumor size [25]. 
Nevertheless, is not always possible to adopt the surgical intervention due to some cancers 
location or other restrictions. In those cases, the most widespread approach chemotherapy. 
Therefore a focus on this technique and the available drugs will be done in the following 
paragraphs.  
Chemotherapy is defined as the use of drugs (usually cytotoxic agents) to treat cancer 
[26]. It is has been used since 1500s, initially administering heavy metals to the patients and 
causing severe toxicity and low efficacy. Since then, more effective chemotherapy drugs were 
studied and commercially available for use as cure, prevention and palliation of a wide range 
of cancers. Most chemotherapy drugs interfere either with the synthesis of DNA, RNA or 
proteins.    
Antineoplastic agents are classified according to their way of action and the phase of 
the cell cycle on which they act. If they are specific to a certain cell cycle phase their 
denomination is cell-cycle specific agents [27][15][28].  
 
1.2.1 Cell	  cycle-­‐specific	  agents	  
1.2.1.1 Antimetabolites	  
These agents are synthesized to mimic natural metabolites, purines, pyrimidines or folates 
involved on the DNA synthesis. Their action occurs on the S-phase of the cell cycle and is 
more effective on high rate growing tumors. Some drugs categorized as antimetabolites are 
capecitabine, gemcitabine, methotrexate and 5-fluorouracil (5-FU). 
 
1.2.1.2 Mitotic	  Inhibitors	  
 They act by causing metaphase arrest. Mitotic inhibitors have activity in G2 and S 
phase, but are most known as M-phase active. Amongst these drugs are vinca alkaloids and 
taxanes. 
 
1.2.2 Cell	  cycle-­‐nonspecific	  agents	  
This is the denomination for antineoplastic drugs that are active through all the cell 
cycle process. These drugs affect the DNA and do not have specificity to cells in the dividing 
process. 
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1.2.2.1 Alkylating	  agents	  
These agents alter DNA structure by a process known as alkylation. The alkylation 
process leads to the destruction of DNA template, causing cell lysis in last instance. Cisplatin, 
carboplatin and Thiotepa are some of the drugs with these properties.  
1.2.2.2 Nitrosoureas	  
These are lipid-soluble drugs that cross blood-brain barrier and destroy DNA by 
alkylation process. Some of the drugs being part of this group are lomustine, carmustine and 
streptozocin. 
 
1.2.3 Antitumor	  antibiotics	  
Most of antitumor antibiotics were isolated from Streptomyces bacteria. These drugs act 
on DNA-directed RNA synthesis and create toxic oxygen-free radicals what will cause DNA 
strand breaks. Doxorubicin, daunorubicin and mitomycin-C are part of this group of 
antineoplastic drugs. 
 
1.2.4 Hormones	  and	  hormone	  antagonists	  
These drugs act by changing the cellular environment and the membrane permeability in 
a way that affects tumor growth. These drugs antagonize and block natural substances that 
stimulate tumor growth. Drugs that fit into this group are, for instance, the artificial 
synthesized sexual hormones.  
 
1.3 5-­‐Fluorouracil	  and	  5-­‐fluorouracil-­‐acetic	  acid	  
5-fluorouracil is well-established chemotherapy drug in clinical use for around 50 
years now [6], mainly prescripted for the treatment of colorectal, breast and aero digestive 
track cancers [29].   
 
 
 
 
Figure  2:  5-­‐FU  and  Uracil  molecules.  These  two  molecules  differ  only  on  the  atom  linked  to  C5,  where  5-­‐FU  has  the  F  and  Uracil  an  H  atom.  [146]  
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This drug is a fluoropyrimidine, with a cytotoxicity mechanism attributed to the 
misincorporation of fluoronocleotides into 
RNA and DNA and to the inhibition of the 
nucleotide synthetic enzyme thymidylate 
synthase 1  (TS). TS is responsible for the 
conversion of deoxyuridine monophosphate 
(dUMP) to deoxythymidine monophosphate 
(dTMP). The TS inhibition results in a 
decreased concentration of dTMP and 
subsequently leads to a lack of deoxythymidine 
triphosphate (dTTP) since dTTP is synthesized 
from dTMP [29].  
5-FU is itself a prodrug that has to be 
converted to fluorodeoxyuridine 
monophosphate (5-FdUMP), 
fluorodeoxyuridine triphosphate (FdUTP) and 
fluorouridine triphosphate (FUTP) – the 
complete metabolic chain of 5-FU inside the 
body can be seen in Figure 3.  
One mechanism for 5-FU action involves DNA polymerase mediated incorporation of 
dUTP and 5-F-dUTP into genomic DNA leading to U/A, 5-FU/A, or 5-FU/G base pairs [30]. 
RNA function is affected through the metabolic conversion of 5-FU in fluorou-uridine 
(FUTP), which is incorporated into RNA [29]. 
Only 1 to 3% of the administered doses of 5-FU were found as part of cytotoxic 
metabolites and more than 80% is fastly degraded. The remaining 19 to 17% 5-FU is excreted 
in the urine, what will decrease 5-FU antineoplastic activity [31]. Its plasma half-life (t ½) has 
been reported as being 10 to 20 minutes. DPD is an enzyme essential for the control of 5-FU 
toxicity since it converts 5-FU to 5-fluorodihydrouracil (FDHU). FDHU is then metabolized to 
5-fluoro-b-alanine, which is later excreted in the urine. Patients with deficit in DPD were 
reported to suffer an increased risk of toxicity [31].   
5-FU is one of the phase-specific cytotoxic agents which is more effective in the S 
phase of the cell cycle, therefore, the longer its plasma half-life, the highest its cytotoxicity. 
                                                      
1 Thymidylate synthase is an essential enzyme in regulation of DNA replication. Impairments in this enzyme can cause 
abnormalities like chromosome breakage and exchange, genetic recombination, etc. It has a much higher activity in rapidly 
proliferating cells than in noncycling cells. [145] 
Figure  3:  5-­‐Fluorouracil  metabolism.  [29]  
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PREDICTIVE BIOMARKERS
Molecular markers that predict
tumour sensitivity to
chemotherapy.
FOLATES
Family of essential vitamins that
act as cofactors in one-carbon
transfer reactions.
TERNARY COMPLEX
A stable complex that is formed
between 5-fluorouracil,
thymidylate synthase and 5,10-
methylene tetrahydrofolate, and
that blocks synthesis of
thymidylate by the enzyme.
rRNA
(Ribosomal RNA). The RNA
component of ribosomes, which
translate mRNA into protein.
tRNA
(Transfer RNA). tRNAs bond
with amino acids and transfer
them to the ribosomes, where
proteins are assembled
according to the genetic code
that is carried by mRNA.
snRNA
(Small nuclear RNA). Small
nuclear RNAs have key roles in
the splicing of pre-mRNA into
mature mRNA.
mRNA
(Messenger RNA). RNA that
serves as a template for protein
synthesis.
TS inhibition. TS catalyses the reductive methylation
of deoxyuridine monophosphate (dUMP) to deox-
ythymidine monophosphate (dTMP), with the
reduced FOLATE 5,10-methylenetetrahydrofolate
(CH2THF) as the methyl donor (FIG. 2). This reaction
provides the sole de novo source of thymidylate, which
is necessary for DNA replication and repair. The 36-
kDa TS protein functions as a dimer, both subunits of
which contain a nucleotide-binding site and a binding
site for CH2THF. The 5-FU metabolite FdUMP binds
to the nucleotide-binding site of TS, forming a stable
TERNARY COMPLEX with the enzyme and CH2THF, thereby
blocking binding of the normal substrate dUMP and
inh biting dTMP synthesis8,9 (FIG. 2).
The exact molecular mechanisms that mediate
events downstream of TS inhibition have not been fully
elucidated.Depletion of dTMP results in subsequent
depletion of deoxythymidine triphosphate (dTTP),
which induces perturbations in the levels of the other
deoxynucleotides (dATP, dGTP and dCTP) through
various feedback mechanisms10.Deoxynucle tide pool
imbalances (in particular, the dATP/dTTP ratio) are
thought to severely disrupt DNA synthesis and repair,
resulting in lethal DNA damage11,12 (FIG. 2). In addition,
TS inhibition results in accumulation of dUMP, which
might subsequently l ad to increased levels of deoxyuri-
dine triphosphate (dUTP)13,14. Both dUTP and the 5-FU
metabolite FdUTP can be misincorporated into DNA.
Repair of uracil and 5-FU-containing DNA by the
nucleotide excision repair enzyme uracil-DNA-glycosy-
lase (UDG)15 is futile in the presence of high
(F)dUTP/dTTP ratios and only results in further false-
nucleotide incorporation. These futile cycles ofmisin-
corporation, excision and repair eventually lead to DNA
strand breaks and cell death.DNA damage due to dUTP
misincorporation is highly dependent on the levels of
the pyrophosphatase dUTPase, which limits intracellu-
lar accumulation of dUTP16,17 (FIG. 2). Thymidylate can
be salvaged from thymidine through the action of
thymidine kinase, thereby alleviating the effects of TS
deficiency (FIG. 2). This salvage pathway represents a
potential mechanism of resistance to 5-FU18.
RNA misincorporatio . The 5-FU metabolite FUTP is
extensively incorporated into RNA, disrupting normal
RNA processing and function. Significant correlations
between 5-FU misincorporation into RNA and loss of
cl nogenic potential have been shown in human colon
and breast cancer cell lines19,20. 5-FU misincorporation
can result in toxicity to RNA at several levels. It not
only inhibits the processing of pre-rRNA into mature
rRNA21,22, but also disrupts post-transcriptional modi-
fication of tRNAs23,24 and the assembly and activity of
snRNA/protein complexes, thereby inhibiting splicing of
pre-mRNA25,26. In addition, rRNA, tRNA and snRNA all
contain the odified base pseudouridine, and 5-FU
has been shown to inhibit the post-transcriptional
conversion of uridine to pseudouridine in these RNA
species27. POLYADENYLATION OF mRNA is inhibited at rela-
tively low 5-FU concentrations28. These in vitro studies
indicate that 5-FU misincorporatio  can potentially
Summary 
• The fluoropyrimidine 5-fluorouracil (5-FU) is an antimetabolite drug that is widely
used for the treatment of cancer,particularly for colorectal cancer.
• 5-FU exerts its anticancer effects through inhibition of thymidylate synthase (TS) and
incorporation of its metabolites into RNA and DNA.
• Modulation strategies, such as co-treatment with leucovorin and methotrexate,have
been developed to increase the anticancer activity of 5-FU.
• Molecular biomarkers that predict tumour sensitivity to 5-FU have been identified,
including mRNA and protein expression levels of TS.
• DNA microarray analysis of 5-FU-responsive genes will greatly facilitate the
identification of new biomarkers,novel therapeutic targets nd the development of
rational drug combinations.
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Figure 1 | 5-Fluorouracil metabolism. 5-Fluorouracil (5-FU;
see structure) is converted to three main active metabolites:
fluorodeoxyuridine monophosphate (FdUMP),
fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine
triphosphate (FUTP). The main mechanism of 5-FU activation
is conversion to fluorouridine monophosphate (FUMP), either
directly by orotate phosphoribosyltransferase (OPRT) with
phosphoribosyl pyrophosphate (PRPP) as the cofactor, or
indirectly via fluorouridine (FUR) through the sequential action
of uridine phosphorylase (UP) and uridine kinase (UK). FUMP is
then phosphorylated to fluorouridine diphosphate (FUDP),
which can be either further phosphorylated to the active
metabolite fluorouridine triphosphate (FUTP), or converted to
fluorodeoxyuridine diphosphate (FdUDP) by ribonucleotide
reductase (RR). In turn, FdUDP can either be phosphorylated
or dephosphorylated to generate the active metabolite  FdUTP
and FdUMP, respectively. An alternative activation pathway
involves the thymidine ph sphoryl se catalysed conversion of
5-FU to fluorodeoxyuridine (FUDR), which is then
phosphorylated by t ymidine kinase (TK) to FdUMP.
Dihydropyrimidine dehydrogenase (DPD)-mediated conversion
of 5-FU to dihydrofluorouracil (DHFU) is the rate-limiting step of
5-FU catabolism in normal and tumour cells. Up to 80% of
administered 5-FU is br ken down by DPD in the liver.
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Due to the small size of 5-FU molecule, which makes it capable of penetrating into 
almost all tissues leading to accumulation through the whole body. This non-selective 
accumulation contributes the worsen the side effects since healthy cells have contact to 5-FU 
as well [11]. 
Considering 5-FU severe side effects, namely myelosuppression and gastrointestinal 
toxicity [6], many efforts have been done to reduce its toxicity and also to improve its 
shortcoming pharmacokinetics. Fast body clearance is an issue associated not only to 5-
Fluorouracil but also with other widespread drugs, some used in cancer therapy as well. This 
leads to higher doses treatments applied to patients, which in its turn leads to more severe side 
effects. 
As an attempt to improve 5-FU antitumor activity and reduce side effects, Tada [8] 
added an acetic acid group to 5-FU having by result a 5-fluorouracil acetate . This molecule 
modification creates a free group that can be accessed to bind FUAc to proteins. Pure 5-FU has 
no functional group compatible with protein high affinity binding [10]. Bertucci et al found 
that 5-FU binds to native human serum albumin with low affinity and low specificity [5].  
Based on previous works of Baker and Cheda (1965) and Tada (1975), where an acetic 
acid group was introduced into the N1 position of 5-FU in order to try an improvement of its 
antitumor activity, Chung et al. [10] synthesized fluorouracil acetic acid-human serum albumin 
conjugates and investigated the pharmacokinetics of 5-FU after intravenous infusion of the 
conjugates.  FUAc was chosen due to its carboxylic group, what makes a conjugation with 
HSA possible. Their results demonstrated that FU rather than FUAC was released from the 
conjugates in vivo, which indicated that FUAc and polymer conjugates could release pure 5-
FU [10]. 
 
1.3.1 Targeted	  drug	  delivery	  
Conventional chemotherapy drugs are distributed in a non-specific way through the whole 
body, though its cytotoxicity will be exerted both on healthy and tumor cells. This lack of 
specificity is a limiting factor since the drug dose achieved in the tumor cannot be as high as 
desirable in order to protect healthy cells and tissues.   
A new approach to chemotherapy started in the last decades, as a try to overcome or at least 
minimize this drawback of chemotherapy [32]. Based on the research done in the last decades 
on tumor molecular and cellular environment scientists started to develop targeted delivery of 
drugs, which, at the same time aim to prolong plasma t ½ of the native drug [33]. Drugs are to 
be released inside or in the vicinity of the tumor, therefore reducing systemic toxicity and 
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increasing the drug concentration in the tumor [34]. An ideal molecule for drug delivery should 
have some characteristics like a relatively high loading capacity for the active substance, to be 
kept in the proximity of the tumor by some process, not trigger an immunologic response by 
the body, do not cause adverse effects by itself and have a good biodegradability [33].  
Several biological and synthetic substances had been use for targeted drug delivery, most of 
them filling the requirements referred in the last paragraph. Substances like PLGA, interferin, 
carbon nanotubes, viruses, liposomes, dendrimers and albumin are in the group of the 
substances already reported as being suitable as a drug carrier [32][35].   
 
1.4 Human	  Serum	  Albumin	  (HSA)	  
Albumin, a protein of 66478 Da and 585 amino acids, is the most abundant of the 
blood proteins, with a concentration of around 35-50 mg/mL [19]. It is estimated that a human 
has about 350g of this protein in total, divided by the blood (150g) and the extravascular space 
(200g) and having an average half-life of 19 days. HSA contains a single Trp residue at 
position 214; Met, Gly, and Ile residues are low however Cys, Leu, Glu, and Lys are abundant. 
The large number of ionized residues gives to HSA a high total charge what enhance its 
solubility [36]. Around 14g of this protein are catabolized every day by a healthy person and 
replaced by new albumin, which is synthesized by hepatocytes and about 15mg are lost by the 
kidneys.  
This serum protein can also leave the capillary system (by transcytosis) and previous 
works showed that during the HSA half-life it runs through 15 000 whole circulation circuits 
plus about 15 trips to extracellular space, returning back to systemic circulation by lymphatic 
system [18]. Among several proteins to which drugs can bind once in the circulating blood, 
albumin is predominantly involved due to its small size and abundance [19]. Albumin is also 
described as a facilitator for endothelial transcytosis of plasma constituents linked to it to the 
extravascular space. That starts by the binding of albumin to a cell surface receptor, which 
leads to formation of transcytotic vesicles by cell membrane invagination [37]. Upon entering 
the tumor interstitium, the accumulation of albumin is possibly facilitated by SPARC (Secreted 
Protein, Acidic and Rich in Cysteine), which has binding affinity to albumin and significant 
homology to gp60, also known as albondin. Gp-60 binds to caveolin-1 (intracellular protein) 
and transcytotic vesicles are formed (caveolae) [38]. The over-expression of SPARC (or 
osteonectin) as a key modulator is associated with increased tumor invasion, metastasis and 
poor prognosis in multiple tumor types [39].  Maeda et al studied the intratumor accumulation 
of different proteins in solid rat tumors, showing that serum albumin is one of the proteins 
which the accumulation is more accentuated [2]. Powell et al [40] studied the influence of 
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estrogen and serum albumin on the proliferation of MDA-MB-231, MCF-7 and T-47D cells. 
Their work suggests that both a membrane estrogen receptor and a membrane albumin-binding 
protein (mABP) are involved on this process. The N-terminal part of HSA was associated with 
the protein inhibitory activity on MCF-7 and T-47D cell lines. MDA-MB-231 suffered no 
inhibitory effect and it was associated with the lack of mABP expression.  
Furthermore, it is a natural carrier of hydrophobic molecules (such as vitamins, 
hormones and other plasma constituents) and has favorable noncovalent binding characteristics 
[37]. Lysine residues represent one of the most reactive groups in albumin. HSA has 59 lysine 
residues [41][42][43].  
 
1.5 Albumin	  and	  therapeutics	  
Human serum albumin is a widely used treatment nowadays for several diseases, for 
instance, shock, burns, trauma, acute respiratory distress syndrome, chronic liver disease, etc. 
Other applications have been developed in the last years, like implantable biomaterials, 
surgical adhesives and sealants, biochromotography, ligand traping and fusion proteins [36]. 
Activated cells such as tumor or inflammatory cells were reported to metabolize albumin in 
order to cover their increased need for amino acids and energy. HSA can also help to adjust 
blood pH since it contains a high percentage of acidic (16,8%) and basic (16,9%) amino acids 
[44]. 
Recently FDA approved a particle of albumin-binded Paclitaxel under the commercial 
designation of Abraxane® (Celgene Corporation), which is currently being administered as a 
first-line treatment to metastic adenocarcinoma of pancreas in combination with gemcitabine 
[45]. Abraxane particles have an average diameter of 130nm and after intravenous injection, 
the albumin-paclitaxel particles quickly dissolve into smaller native albumin-sized 
(approximately 10nm) complexes, which allow intravenous infusion without the risk of 
capillary blockage [46].  This formulation made possible the delivery of paclitaxel to tumors 
with a 4.5-fold increase in its transport across endothelial cells, creating an enhanced 
intracellular paclitaxel delivery and, consequently, increased activity [47]. 
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The nab-paclitaxel reaches the tumor interstitium through the EPR effect. It is believed 
that the particles’ uptake process is the same described for albumin in section 1.4 and 
illustrated in Figure 4. The expression of SPARC in vivo experiments led to an improved 
therapeutic response with nab-paclitaxel when compared to pure paclitaxel. Thus, SPARC 
could serve as a biomarker for the response to therapy with nab- paclitaxel [47]. 
 
Another conjugate particle with albumin and methotrexate (MTX) was described in 
several publications and subjected to clinical studies [48][49][50]. They found that MTX-HSA 
had a delayed effect on the cell cycle compared with MTX and that free MTX was more 
cytotoxic than MTX-HSA conjugates on a tumor cell line. An interesting fact reported was the 
plasma half-life of MTX-HSA, estimated to be up to 3 weeks, contrasting with pure MTX 
plasma half-life of up to 24 hours. The distribution pattern of these conjugates (1M MTX per 
HSA) in healthy rats and rats with tumor was indistinguishable from the distribution of native 
HSA. High tumor accumulation rates for both HSA and the MTX-HSA conjugate were 
observed (more than 15%) after 72 h in rats with Walker-256 carcinoma. 
Chung et al [10] tested a FUAc-HSA conjugate in rabbits, however the procedure 
followed for synthesize the particles was not described. An infusion of FUAc-HSA for 30 
minutes was reported to maintain a plasma concentration of 5-FU of 1µg/mL from 3 to 24 
by the FDA in 2005 for the treatment ofmetastatic breast cancer and has
meanwhile been approved in 41 countries around the world.
Dosed at a higher maximum tolerated dose of 260 mg/m2 taxol
equivalent compared with Taxol®/CremophorEL at 175 mg/m2 in a
3-weekly schedule, the randomized phase III study in 460 patients
with metastatic breast cancer that was relevant for approval by the
FDA, demonstrated a statistically signiﬁcant higher response rates
(33% versus 19%, P=0.001), longer time to tumor progression (23.0
versus 16.9 weeks, P=0.006), and increased survival in the subset
of patients receiving second-line or greater treatment (65.0 versus
55.7 weeks, P=0.024) [5].
Abraxan ® avoids the use of cremophor, and was generally well
tolerated as a 30 min intravenous infusion, and despite the lack of
pre-medication with corticosteroids no hypersensitivity reactions
were observed. Th se encouraging results wer also see in a com-
parison of Abraxane® with Taxotere® (polysorbate-based docetaxel)
in a randomized phase II clinical trial of ﬁrst-line treatment of 300 pa-
tients with metastatic breast cancer [6] at lower doses on a weekly
schedule, either at 100 mg/m2 or 150 mg/m2 taxol equivalents com-
pared with Taxotere® at 100 mg/m2 on a 3-weekly schedule. Progres-
sion-free survival was increas d by approximately 5 months and both
doses of Abraxane® were associated with an improved safety and tox-
icity proﬁle compared with docetaxel.
American Bioscience have extended the evaluation of Abraxane®
to other tumor indications including non-small cell lung carcinoma
(NSCLC), pancreatic cancer, melanoma, and head and neck cancer,
often in combination with conventional chemotherapy [6–8].
As an example, metastatic pancreatic cancer has a very poor prog-
nosis and gemcitabine or 5-ﬂuoururacil are to date the only approved
drugs with a response rate of 10–20% and an improvement in survival
in the order of 2 months. In a phase I/II study the combination of
Abraxane® at 125 mg/m2 paclitaxel equivalents and gemcitabine at
1000 mg/m2 on days 1, 8, and 15 in 44 patients with metastatic pan-
creatic cancer, a disease control rate of 80% and median overall sur-
vival of 12.2 months was achieved [9]. As shown in Fig. 9 for one
patient, rapid and signiﬁcant responses were observed via PET
scans. A phase III trial in patients with advanced pancreatic canc r is
ongoing to further evaluate the efﬁcacy of this combination.
One of the most interesting aspects of Abraxane® is the detailed in-
sights into itsmodeof acti n that has been obtained preclinically aswell
as clinically. Abraxane®, although stable as a nanoparticle in its galenic
formulation, dissolves rapidly after intravenous infusion resulting in
soluble albumin-boun paclitaxel complexes having a size basically
comparable to that of endogenous albumin. The albumin-paclitaxel
complexes accumulate in the tumor through the well-established en-
anced and permeation effect of solid tumors, but a further albumin
transport pathway mediated by the 60-kDa glycoprotein gp60, also
known as albondin, located on the endothelial cell surface seems to be
responsible for tumor uptake and above all for the even tumor distribu-
tion of Abraxane® and the subsequent release of paclitaxel [10–12].
Fig. 10. Uptake of albumin-paclitaxel nanoparticles is presumably mediated by the gp60 transcytosis pathway and subsequent binding to SPARC (Secreted Protein, Acidic and Rich
in Cysteine) in the tumor extracellular matrix.
Illustration provided with kind permission of Dr. Rafﬁt Hassan, M.D., National Cancer Institute, USA.
8 B. Elsadek, F. Kratz / Journal of Controlled Release 157 (2012) 4–28
Figure   4   Presumable   uptake   of   albumin-­‐paclitaxel   nanoparticles.   Possibly,  FUAc-­‐HSA  walkthrough  the  same  process.  Gp60  is  a  mediator  of  albumin  drug  complexes   to   transcytosis.  After   the   releasing  of   the   complexes   in   the   tumor  insterstitium,  they  bind  to  SPARC  (Secreted  Protein,  Acid  and  Riche  Cysteine)  in  the  tumor  extracellular  matrix.  [39]  
Introduction 
 30 
hours. Pure 5-FU plasma half-life was of approximately 8 minutes. It was suggested that the 
releasing of pure 5-FU from the compound was triggered by the breaking of the side chain 
occurring in the slightly acidic environment in tumors. No 5-FU was detected after the infusion 
of FUAc. Free FUAc was not detected in rabbits’ blood when after infusion of FUAc-HSA.  
Koziol et al [11] published a work similar to the one described in this thesis, although 
binding FUAc to Bovine Serum Albumin (BSA) instead of Human Serum Albumin. 12 
molecules of FUAc were covalently bound to each BSA molecule and the cytotoxicity of the 
conjugate was tested with breast carcinoma cell lines (MDA-MB-231 and T-47D). These two 
cell lines differ in one membrane receptor, the gp60, considered to play a central role in cell 
uptake of albumin conjugates. The results obtained suggested an influence of this receptor in 
the conjugate cytotoxicity. For T-47D cell line, the one with gp60 receptor, the reported IC50 
value was 88,6µM against 408µM for MDA-MB-231. These two cell lines were also incubated 
with FITC-BSA for 72 hours and there was an obvious discrepancy in albumin uptake between 
them when observed under the confocal laser scanning microscope. 
	  
1.6 Drug	  discovery	  procedures	  
Drugs are, usually, discovered through insights into specific disease processes, 
unexpected effects of treatments in test and due to new technologies, providing the opportunity 
of trying a new approach [51].  
When a promising compound is identified, researchers should conduct their 
experiments in order to assess, amongst others variables, to how the drug is absorbed, 
distributed, metabolized and excreted, its potential benefits and mechanisms of action, side 
effects, interaction with other drugs and its effectiveness when compared with similar drugs 
[51]. Once this phase is completed, tests with cells in culture are nowadays quite a wide spread 
practice. In the case of promising results with the cell culture, animal and clinical trials could 
be approved in to test further treatment efficiency and side effects.  
 
1.6.1 Cell	  lines	  
Nowadays, hundreds of cell lines are commercially available. Only The American 
Type Culture Collection (ATCC) itself, one of the most important cell line suppliers 
worldwide, currently holds more than 4000 cell lines from 150 species.  
When it comes to drug discovery procedures, isolated cell lines play an important role 
by making possible to evaluate if the tested agent is effective and by enabling access to toxicity 
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profiles of the drug in a certain tissue. Drug screening in cells represent an important early 
evaluation insofar as it can stop a drug screening before animal and human tests if in vitro 
results are not enough satisfactory [52].  
Cells isolated from a disease site, containing genetic or biochemical abnormalities, 
alteration in receptors, ion channels and receptor signaling pathways are a particularly useful 
tool as they provide a preview of particular pathways in a drug action [53].  
 With anti-cancer drugs being one of the most research-focused areas worldwide, 
panels of cancer cell lines have been used in order to test the crescent number of novel-
developed drugs, namely by The US Cancer Institute (NCI). This American organism, maybe 
the best known working in this matter, developed in the late 1980s the 60 human tumor cell 
line anticancer drug screen (NCI60) intended to be a tool to supplant the use of transplantable 
animal tumors for antitumor drug screenings [54]. MDA-MB-231, MCF-7 and T-47D are 
included in NCI60 as part of the breast cancer cell lines panel. These are object of numerous 
published works and therefore very well characterized.  
 
1.6.1.1 Membrane	  receptors	  and	  proteins	  expressed	  by	  the	  three	  cell	  lines	  
The three breast cancer cell lines (MDA-MB-231, T-47D and MCF-7) were already 
subject of many publications; therefore it was possible to collect information about the 
expression of proteins relevant to cells characterization.  
It is advocated by several health institutions that breast cancers should be tested for 
estrogen and progesterone receptors and HER2 as a standard [55][56]. To test cancers for these 
receptors can make the difference when it comes to choose an adequate treatment. Breast 
cancers classified as triple negative (negative for estrogen, progesterone and HER2) are often 
associated with poor prognosis since most drugs are set to target one of those three receptors.  
Other receptors have been referred as playing a role in breast cancer characterization and 
therefore, in a better treatment design. mABP, SPARC and caveolin were reported to be 
involved on the uptake of albumin and albumin-bound drugs [13]. SPARC and mABP are 
referred later on this work in a more detailed manner. Calcitonin was referred as involved in 
cell growth, differentiation and tissue development [57]. The androgen receptor was associated 
with lower risk of recurrence in patients with all breast cancer types [58]. Breast cancer 
positive for estrogen receptor was found to be inhibited by glucocorticoids [59]. Referring to 
prolactin, an excess of this hormone was reported as an indicator of disease progression and 
poor prognosis [60]. Higher concentrations of the CD133 protein are correlated with increasing 
in tumor size, metastasis and advanced clinical stage [61].  
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 In Table 1 are listed the receptors and membrane-proteins already referred and the 
characterization of the three cell lines chosen for this work. 
 
Cell line Receptors and membrane-proteins 
  mABP 
SPAR
C 
Calcito
nin 
Androg
en 
Estroge
n 
Progest
erone 
Glucocor
ticoid 
Prolact
in 
HE
R2 
CD
133 Caveolin-1 
T-47D + - + + + + + + + - reduced 
MDA-
MB-231 
- - - - - - - + - + low 
MCF-7 + + + + + + + + - - very low 
  Table  1:  Relevant  receptors  of  T-­‐47D,  MDA-­‐MB-­‐231  and  MCF-­‐7  cell  lines.  [62][63][40][64][65]  
 
1.7 Motivation	  –	  resume	  of	  the	  theoretical	  background	  	  
The antineoplastic drug 5-Fluorouracil is used for treating several types of cancer, 
namely breast cancer. Its plasma half-life was reported to be approximately 20 minutes, which 
is a very short period, and its toxicity affects both healthy and tumor cells. HSA is an abundant 
serum protein with a circulating life of approximately 19 days and benefiting of EPR to 
achieve tumors interstice. HSA was described to be preferentially accumulated in the tumors 
vicinity [66][2]. Considering HSA attributes, it appears as a strong candidate for drug targeting 
vehicle.    
 However, in order to bind covalently 5-FU to HSA a linker needs to be considered 
since 5-FU does not have a free reactive group to bind a protein.   
Chung et al [10] reported the pharmacokinetics of a FUAc-HSA conjugate, however 
the synthesis process was not clarified. 5-FU was detected in blood for up to 24 hours when 
rabbits received an infusion with FUAc-HSA conjugates.  
 Kim et al [9] tested 5-FU release from FUAc-HSA particles in physiological solutions 
and varying pH and reported a high stability of the conjugate. The percentage of 5-FU released 
from the particles at a pH of 9 was 1%.  
  The cytotoxicity power of a FUAc-albumin conjugate in breast cancer cells was 
published by Koziol et al [11]. The conjugates were synthesized with bovine serum albumin 
for economical reasons, since it is considerably cheaper and highly similar to the human 
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protein. FUAc-HSA was reported to cause strong inhibition of cell metabolism mainly in cells 
with mABP, a membrane protein that is a recognition site for albumin. 
 Considering these facts, the work reported in this thesis followed the line of the work 
performed previously by Koziol et al, however substituting BSA for HSA. As the protocol for 
FUAc-BSA was available and already tested it was decided to follow it for FUAc-HSA 
synthesis. One more cell line was added to the test panel, another breast cancer cell line 
positive both for SPARC and mABP (gp60). The concentrations to test in cell culture were 
also adjusted to lower values to keep concentrations closer to the ones reported for plasma of 
oncologic patients in clinical treatments. 
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2 Materials	  and	  Methods	  
2.1 Materials	  
 
In this section will be listed the materials used within this project. Chemical substances 
and equipment are listed in separate. 
 
2.1.1 Equipments	  and	  consumables	  
 
Material Model Supplier 
Centrifugal filtration tubes Amicon Ultra-15 Centrifugal Filter Units (30 kDa) Millipore GmbH 
Centrifuge Heraeus Labofuge 400 Heraeus Instruments GmbH 
50 mL centrifugal tube Red cap, assembled, sterile, non-pyrogenic Sarstedt AG & Co. 
Rolling mixer Assistent RM 5 Karl Hecht GmbH 
Laboratory glass material - KAVALIERGLASS, a.s. Ltd 
Magnetic mixer Hytrel HTR 8068 Carl Roth GmbH 
Digital pH meter Jenco model 60 Jenco International 
Cell culture flasks 75 cm2 Growth surface TPP Techno Plastic Products 
Centrifuge Heraeus Labofuge 400 Heraeus Instruments GmbH 
50 mL centrifugal tube Red cap, assembled, sterile, non-pyrogenic Sarstedt AG & Co. 
Clean bench Thermo HERAsafe Heraeus Instruments GmbH 
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CO2 Incubator BINDER CB Series BINDER GmbH 
Automatic pipette Automatic-Sarpette Sarstedt AG & Co. 
Serological pipettes (5, 10 and 
25 mL) Individual wrapped, sterile Corning GmbH 
Counting chamber Nebauer Improved LO Laboroptik 
Scale Explorer Ohaus Ohaus Europe GmbH 
Inverted microscope Leica Leitz DM IL Leica Mikrosysteme Vertrieb GmbH 
8 channel pipettor 20-200 µL VWR GmbH 
Microplate Spectrophotometer Power wave 340 Bio-Tek 
BD Falconcell strainer 40 µm Nylon Corning GmbH 
Cryopresrvation cell tubes CryoPure Tube, 1.6 mL white Sarstedt AG & Co. 
96 well plates Falcon, flat bottom, low evaporation Corning GmbH 
24 well plates Costar, flat bottom Corning GmbH 
Microscopy cell culture plates Ibidi µ-Slide 8 well Ibidi GmbH 
Syringe Sterile Filter 0.24µm MiniSart  Sartorius AG 
Vortex Vortex-Genie 2 Scientific Industries 
Water bath Lauda MS Lauda Dr. R. Wobser GmbH 
MALDI-TOF analyzer  Bruker Autoflex Speed Bruker equipment (Rheinstetten, Germany 
CD-Spectrometer JASCO J-720 Japan (Tokyo, Japan) 
JASCO Labor-und Datentechnik 
GmbH 
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Confocal laser scanning 
microscope ZeissLSM 510 meta 
Zeiss MicroImaging GmbH, Jena, 
Germany 
NanoDrop Spectrophotometer NanoDrop 1000 Thermo Scientific 
Table  2:  Equipment  and  consumables  used  for  the  work  in  this  project  
 
2.1.2 Chemicals	  and	  reagents	  
All the substances used during this work are listed below, together with its molecular 
weight and the supplier.  
 
Substance Molecular Weight (Da) Supplier 
5-Fluorouracil >99% (HPLC) 
powder 130,08 Sigma Aldrich GmbH 
Albumin from Human serum, 
96-99%, Lyophilized 66478 Sigma Aldrich GmbH 
Phosphate Buffered Saline 
(PBS), powder, pH 7.4 - Sigma Aldrich GmbH 
Ampuwa Water, steril and 
endotoxin free - 
Fresenius Kabi Deutschland 
GmbH 
FUAc (previously 
synthesized) 188,1 - 
Sodium chloride (NaCl) 58,44 Merck KgaA 
Sodium Hidroxide (NaOH) 39,99 Merck KgaA 
2-(N-Morpholino) 
ethanesulfonic acid (MES) 195,2 Sigma Aldrich GmbH 
1-ethyl-3-(3-
dimethylaminopropyl)carbodii
mide hydrochloride (EDC) 
191,7 Sigma Aldrich GmbH 
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N-hydroxysuccinimide (NHS) 115,1 Sigma Aldrich GmbH 
GIBCO Fetal Bovine Serum - Life Technologies GmbH 
Penicillin/Streptomycin 
(PenStrep, 10.000 Units/mL, 
10 mg/mL) 
334,39/581,57 Life Technologies GmbH 
Roswell Park Memorial 
Institute Medium (GIBCO 
RPMI 1640 Medium) 
GlutaMAX 
- Life Technologies GmbH 
Trypsin (0,25 % + EDTA (1x) 
with Phenol red) - Life Technologies GmbH 
Chloroacetic Acid (C2H3ClO2) 94,5 J.T. Baker 
Eagle's Minimum Essential 
Medium (EMEM) - 
American Type Culture Collection 
(ATCC), LGC Standards GmbH 
Human recombinant insulin 
0.5 mg/mL, 5mL bottle 
(C254H377N65O75S6) 
5808 Biochrom AG 
Dimethylsulfoxid (DMSO, 
C2H6OS) 99.5% 
78,13 Carl Roth GmbH 
Acetic Acid 99-100% 
(C2H4O2) 
60,05 J.T. Baker 
Hydrochloric Acid Fuming 
37% (HCl) 36,46 Merck 
Potassium Chloride (KCl) 74,55 VEB Jenapharm 
3-(4,5-Dimethylthiazol-2-yl)-
2,5-
Diphenyltetrazoliumbromid 
(MTT,C18H16BrN5S) 
414,32 Sigma Aldrich GmbH 
Sodium Hydrogen carbonate 
(NaHCO3) 
84,01 Merck KgaA 
Hydrochloric Acid 37% (HCl) 36,46 J.T. Baker 
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Sodium dodecyl sulfate (SDS, 
C12H25NaO4S) 
288,38 Sigma Aldrich GmbH 
Dihydrorhodamine 123 346,38 Glycotope Biotechnology 
Trypan Blue (0,25% [w/v], 
C34H28N6O14S4) 
872,88 BioChrom AG 
Table  3:  Chemicals  and  reagentes  used  during  the  work  in  this  project  
 
The formulation of solutions prepared in the laboratory is described in the table below. 
 
Solution Formulation 
Culture media for MDA-MB-231 and 
T-47D cell lines RPMI 1640, 10% FBS, 1% PenStrep 
Culture media for MCF-7 EMEM, 10% FBS, 1% PenStrep, 0,01 mg/mL human 
recombinant insulin 
MTT stock solution 1 mg/mL MTT powder in RPMI 1640 or EMEM (depending on the cell line being used) 
Solubilization solution for MTT 
0,1 g/mL SDS, 0,6% Acetic Acid, 99,4% SDS Table  4:  Solutions  prepared  in  the  laboratory  and  its  formulation  
 
For DNA extraction from cultured cells, a commercial kit from Qiagen® was 
purchased. Its commercial designation is QIAamp® DNA Mini and Blood Mini kit.  
 
2.1.3 Cell	  Lines	  
 From the 3 cell lines kept in culture, T-47D and MDA-MB-231 were obtained from 
other research groups working at Charité (MDA-MB-231 from PD Dr. Diana Lüftner working 
at Department of Medicine - Division of Hematology, Oncology and Tumor Immunology; T-
47D from Prof. Dr. Kurt Possinger from Medical Clinic of Oncology and Hematology) and 
MCF-7 was purchased from ATCC.  
All of them were isolated breast cancers cells and grow as adherent in culture. 
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2.1.3.1 T-­‐47D	  cell	  line	  
This cell line was isolated from a 54-year-old female, from the mammary gland with 
ductal carcinoma. It is an epithelial cell type, hypotriploid, derived from a pleural effusion in a 
metastic site.[62] 
 
2.1.3.2 MDA-­‐MB-­‐231	  cell	  line	  
 This is an epithelial cell line, isolated from 51-year-old Caucasian female mammary 
gland with adenocarcinoma. The cells were collected in a pleural effusion derived from 
metastic site. Cells are aneuploid female. [62] 
 
2.1.3.3 MCF-­‐7	  cell	  line	  
 Epithelial cells isolated from mammary gland with adenocarcinoma of a 69 year old 
Caucasian woman. Collected from a pleural effusion derived from a metastic site. [62] 
 
2.2 Methods	  
In this section are described the methods and techniques performed within this work. 
The first FUAc synthesis was performed by Dr. Torsten Sievers and later repeated by me and 
Michael Koziol according to the protocol developed by Dr. Sievers. The first FUAc-HSA 
synthesis was performed by Michael Koziol and Dr. Yu Xiong. NMR spectroscopy was 
performed by Dr. Torsten Sievers and MALDI-TOF by Dr. Felix Wojcik. The CD-
Spectroscopy was performed by me and Heike Nikolenko. All the procedures related with cell 
culture and cytotoxicity assays (MTT and cell counting) and DNA extraction were performed 
by me, with the help of Kathrin Smuda whenever necessary. Kathrin Smuda and Michael 
Koziol introduced me o these procedures. Dr. Radostina Georgieva and I performed CLSM 
procedures. Every step of this work was discussed within the workgroup in order to find the 
most suitable way to proceed.      
2.2.1 	  FUAc	  synthesis	  
FUAc reaction was adapted from previous works of Baker and Cheda (1965) and Tada 
(1975), where an acetic acid group was introduced into the N1 position of 5-FU (see Figure 5). 
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FUAc firstly used in this work was synthesized by Michael Koziol and Torsten Sievers 
as described in Koziol et al. [11].  
 
A new charge of FUAc was synthesized by June at Biotechnology laboratory from the 
Institute of Transfusion Medicine of Charité, according to the procedure described by Tada [8] 
and adapted as described at Koziol et al [11]. All procedures were performed at room 
temperature and most steps took place in the fume hood due to the possible occurrence of 
harmful fumes. Chemicals were used as provided by suppliers (see at Materials section) with 
no further purification. 
First, 9,76g of 5-Fluorouracil (0,157 g/mL) were dissolved in 62mL of water 
containing 8,41mg of KOH (0,1356 mg/mL) (solution 1). 7,05mg of chloroacetic acid were 
dissolved in 28,2mL (0,25 mg/mL) of water and poured into the 5-FU solution (solution 1) and 
stirred for 15 minutes. A white precipitate was formed and was solved by adding enough 
potassium hydroxide (KOH) for the precipitate to solve, what happened around pH 10. Mixture 
was again stirred for 15 minutes, keeping pH at 10. The solution was then heated to 100°C and 
boiled under reflux for 2 and a half hours. Solution was then cooled down to room temperature 
and pH adjusted to 2 by the addition of concentrated hydrochloric acid. Then, the solution was 
kept at 4°C for 1 hour and pH was readjusted to 2. After setting the pH, solution was left at 
4°C for 24 hours to allow the crystallization of FUAc. 
After the 24 hours, the tube was centrifuged to separate FUAc needles from the 
supernatant. The FUAc needles were then solved in saturated aqueous NaHCO3, in the 
necessary volume to obtain a clear solution. 
Afterwards, the remaining supernatants were left to crystalize more 2 times, at 4°C and 
with pH adjusted to 2 with hydrochloric acid, followed by centrifugation to separate needles 
and supernatant. The last step was to dry FUAc, what was done with the help of a vacuum 
bomb, at the pressure of approximately 0.1mbar at room temperature. The product obtained 
from the 3 crystallizations was dried separately in order to confirm their possible different 
conformation later, by NMR. 
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Fluorouracil acetic acid (FUAC) was first chemically
bound to dextran in a solvent mixture (FA/DMF/
DCM ¼ 10 : 9 : 1, v/v/v) catalyzed by DMAP and DCC.
The conjugate obtained was confirmed by analysis of
UV, IR and NMR spectra. The degree of substitution
(DS) of the conjugates was dependent on the propor-
tions of FUAC and dextran used in the reaction mixtu-
re. Investigation of the chemical stability revealed that
the conjugate was stable in an acidic buffer solution.
The conjugate will find application in drug targeting and
controlled release.
5-Fluorouracil (FU) is widely used in the treatment of var-
ious kinds of cancer including colon cancer. But due to its
serious adverse effects, many efforts have been made to
decrease its side effects and increase its therapeutic index.
To achieve good therapeutic effects, 5-FU needs to be
kept at a low concentration and to act over a long time
(Longley et al. 2003). Considering the mechanism of FU,
Chung et al. (1991) synthesized fluorouracil acetic acid-
human serum albumin conjugates and investigated the
pharmacokinetics of FU after intravenous infusion of the
conjugates. Their results demonstrated that FU rather than
FUAC was released from the conjugates in vivo, which
indicated that FUAC and polymer conjugates can release
FU in vivo.
Dextran has been investigated as a most promising carrier
for the delivery of drugs, proteins, enzymes and imaging
agents (Mehvar 2000). Most dextran conjugates act as
polymeric prodrugs, prolonging the release of the active
drug in vitro and in vivo. In view of the mechanism of
action of FU and the advantages of polymeric prodrugs,
dextran was selected as the carrier for synthesis of a novel
macromolecular prodrug of FU. We anticipated that the
macromolecular prodrug would be stable in vitro and
would slowly release FU in vivo with passive targeting
ability.
Dextran has numerous hydroxyl groups in the glucose
unit. Theoretically dextran can be directly esterified with
bioactive compounds containing carboxyl groups. Because
FU does not have an appropriate functional group to con-
jugate with the hydroxyl group of dextran, FU was re-
acted with chloroacetic acid in the presence of potassium
hydroxide to obtain FUAC and a carboxyl group was thus
introduced to the FU molecule. Then FUAC was esterified
with dextran as shown in the Scheme. The reaction was
performed under conditions similar to the method (Bam-
ford et al. 1986; Nichifor et al. 2004). The DS of the con-
jugates depended on the molar ratio of FUAC and glucose
units. We tried various solvents such as DMSO, MF and
DMF as the reaction medium but the DS of FUAC was
much lower than that of the conjugate prepared in the
mixed solvent. The solvent mixture MF/DMF/DCM was
the best reaction medium among DMSO, MF and DMF,
which was consistent with the results obtained from the
reaction of dextran with other bioactive molecules contain-
ing a carboxylic group (Bamford et al. 1986; Nichifor
et al. 2004). The reasons for the increased efficacy of the
esterification reaction in the mixture (MF/DMF/DCM) are
not clear (Nichifor et al. 2004). However, the FUAC-dex-
tran conjugates were successfully prepared in two steps as
shown in the Scheme.
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SHORT COMMUNICATIONS
Figure  5  Reaction  of  5-­‐FU  to  FUAc  [147]  
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2.2.2 Nuclear	  Magnetic	  Resonance	  Spectroscopy	  
 
Nuclear magnetic resonance is one of the most important tools available to characterize 
molecules. It gives information about relative positions and numbers of spin active nuclei and 
makes it possible to identify the structure of a compound.  
In dependence on the applied magnetic field and the used resonance frequencies you 
can measure the spectra of different atoms present in the molecules. 
There are several NMR different spectra, namely 1H-NMR, 13C-NMR, 19F-NMR and 
31P-NMR. These referred spectra correspond to the NMR record of different atoms present in 
the molecules that constitute the material under 
analysis. These come from different characteristic 
spin (I) and spin angular momentum that nuclei of 
some elemental isotope has, and consequently, a 
magnetic momentum (µ). When applied an external 
magnetic field (B0), nuclei’s magnetic moment will 
be affected by it, resulting in an energy change [67]. 
These so called spin states can have 2I+1 
values for a nucleus with spin I, what corresponds 
to the direction of the angular momentum relative to 
a z-axis, which is by convention chosen as having 
the same orientation of the applied magnetic field. When a nuclei has spin of ½ or -½, these 
corresponds to the magnetic quantum number mI=½ and -½, respectively (Figure 6). 
When there is no applied B0, the two 
levels have equal energy, -½γB0 for parallel with 
B0 and ½γB0 for anti-parallel to B0, with γ being 
the gyromagnetic ratio, a property of the nucleus 
under analysis.  
ΔΕ, the energy separation of 2 levels is 
described by Bohr’s resonance condition: ∆Ε = ℎν! = !!! 𝜔!  (Equation 1) and by 
knowing this and the temperature in Kelvin (T), 
the Boltzmann relation gives the distribution of 
2 
technologies and better design of the RF probes collectively opened new frontiers of 
NMR applications in life sciences.  
In 1971, Damadian showed that the 1H relaxation rates of water, present in 
normal and malignant cells, are different. This opened up the possibility of using this 
property for medical diagnosis. Paul Lauterbur used magnetic field gradients to 
localize NMR signal information in space. He showed that this can be used to 
generate images of objects. This gave birth to the technique called Magnetic 
Resonance Imaging (MRI). Richard Ernst used phase and frequency encoding and 
FT for obtaining MR images, which formed the basis of commercial MRI 
instruments. Peter Mansfield developed the technique of echo-planar imaging (EPI), 
which provides images much more rapidly than the earlier methods. Lauterbur and 
Mansfield received the Nobel Prize in 2003.  
In this Chapter, the basic concepts of NMR spectroscopy are described. These 
may be particularly useful for those who do not have previous knowledge of NMR. 
Some readers may prefer to skip the mathematically oriented sections in the book 
and straight-away turn to applications. Those who want to go deeper into the 
theoretical and experimental aspects of NMR may consult the more advanced text 
books s ggested at the end f ea h Chapter. 
1.1 Quantum Mechanical Model for Spin-1/2 Nuclei 
The basis of NMR spectroscopy lies in the fact that certain atomic nuclei possess 
 
Bo hQo = 2PBo
|E!{ _1/2> E = PBo =  +J,Bo = +½JBo
|D!{ _1/2> E = PBo =  J,Bo = ½JBo
 
Figure 1.1: Energy levels for a nucleus with spin ½, in the presence of a magnetic field (B0). 
The lower level (|D!) has the nuclear spins aligned parallel (mI=½), while the upper energy 
level (|E!) has the spins aligned anti-parallel (mI=-½), relative to the applied magnetic field 
B0. Note that  J=P/IhS. 
 
spin (I; discovered by Goudsmit and Black in 1926) (and spin angular momentum) 
and consequently, a magnetic moment (P). According to the quantum theory, angular 
momentum is quantized. The interaction of the magnetic moment of such nuclei 
with an external magnetic field (B0) results in an energy manifold (Figure 1.1). 
There are 2I+1 stationary or energy eigenstates (also called spin states) for a nucleus 
having spin I, correspon ing to the direction of the angular momentum relative to an 
arbitrary axis z. For the simplest case of nuclei with spin ½, there are two spin states, 
corresponding to the magnetic quantum number mI =½ and -½, respectively. The 
two spin states referred above are identified by the eigenfunctions, |D> (mI = ½) and 
|E> (mI = -½).  
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Figure  6:    Energy  levels  for  a  nucleus  with  spin  ½,   in   the   presence   of   a   magnetic   field   (B0).  The   top   energy   level   has   the   nuclear   spins  aligned   in   parallel   (mI=½)   with   B0   and   the  lowest  energy  level  has  the  spins  aligned  anti-­‐parallel  (mI=-­‐½)  with  B0.  Image  adapted  from  [67] 
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frequency falls in the radio frequency (RF) region and lies in the low frequency 
region of the electromagnetic spectrum. At this magnetic field, the difference of 
population between the states D and E is only about 0.001%. This population 
difference determines the number of photons absorbed during the upward transition 
and thus the strength of the NMR signal. Therefore, NMR is intrinsically a very 
insensitive technique.  
Modern techniques use pulse NMR, which is discussed later. The positive z–
axis (longitudinal axis) is conventionally chosen as the direction of B0. However, 
some books use the convention of placing B0 along –z-axis. This does not make any 
difference, except to change the sign of energies corresponding to the two spin 
states. NMR signal is usually detected by placing a receiver coil in the x-y plane 
(transverse plane) which is perpendicular to the z-axis.  
 1.2 Classical Model  
Both classical and quantum mechanical viewpoints are integral parts of concepts in 
NMR spectroscopy. In the classical approach, the phenomenon of NMR is discussed 
in terms of n t magnetization (M), in a macroscopic sample containing a large 
number of nuclei under study, rather than the behaviour of individual spins. In the 
presence of B0, the angular momentum of the nucleus causes a precessional motion 
around the z-axis (Figure 1.2). The angular velocity of such a motion is given by Z0 
= -JB0. 
       
Precessional
orbit
B0
Nuclear magnetic
dipole ȝ
Spinning proton
 
 
Figure 1.2: Larmor precession of a spin in magnetic field. 
 
In the presence of B0, more nuclei align in the parallel direction resulting in a net 
magnetization in the z direction (Mz). If an oscillating radiofrequency field (B1) with 
a frequency equal to Z0 is now applied in y-direction for a short time (t), then the net 
magnetization nutates (flips) from the z-direction towards x direction. The flip-angle 
due to such an RF pulse, is given by T = JB1t (radians), where B1 and t are the 
strength and the time duration respectively, of the applied RF field. To start with, all 
spins precess with the same phase, after the application of RF field. This results in a 
transverse magnetization (Mx/y). In other words, the RF pulse creates a phase-
coherence among different precessing spins.  
CHAPTER 1 
Figure   7:   Illustration   of   the   different  physical   quantities   to   define   the   Larmor  frequency.  [67]  
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spin population in a sample, with 𝜅 being the Boltzmann constant, υ! the Larmor frequency 
and ℎ the Planck constant: 𝑒𝑥𝑝 − !!!" = exp − !!!!" ≈ 1 − !!!!"       Equation  2:  Boltzmann  relation  
Larmor frequency (Figure 7) or the precessional frequency of the nucleus is usually 
expressed in Hertz and 𝜔! 2𝜋ν! , the angular precessional frequency of the nucleus, is 
expressed in radians per second. These frequencies depend on both the gyromagnetic ratio (γ) 
of the nucleus and B0.  
𝒉𝟐𝝅 𝝎𝟎 = 𝟐𝝁𝑩𝟎  Equation  3  so  𝝎𝟎 = 𝜸𝑩𝟎,  with  𝜸 = 𝝁𝑰 𝒉𝟐𝝅   Equation  4    
From Equation 3 and Equation 4 it is possible to conclude that the resonance 
frequency (𝜔!) is different for different nuclear spins as the gyromagnetic ratio is different for 
each spin and it is proportional to the applied magnetic field.  
NMR signals are usually detected by means of a receiver coil in the x-y plane, taking 
the z-axis as defined according to the B0 orientation. The above theory refers to the quantum 
mechanical model for nuclei. 
In the classical model, the main variable is the net magnetization (M) of the 
macroscopic piece composed by a large number of nuclei. When a magnetic field is applied, 
the angular momentum of the nucleus will cause a precession around the B0 orientation, with 
the same nature as described for the nuclei (Figure 7) with angular velocity 𝝎𝟎 = −𝜸𝐁𝟎.  
Nuclear magnetic resonance decoupling is a technique where the analyte is irradiated 
with a specific frequency to eliminate completely or partially the coupling effect between 
nuclei. This coupling effect is the effect exerted from one atom to the others in its proximity.  
 Common NMR spectroscopy spectra are presented as a chemical shift on x-axis vs 
signal intensity (y-axis). Chemical shift is a measure of how far the registered signal is from a 
reference signal (usually tetramethylsilane - TMS). 
𝛿 𝑝𝑝𝑚 = 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒  𝑑𝑜𝑤𝑛𝑓𝑖𝑒𝑙𝑑  𝑓𝑟𝑜𝑚  𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒  𝑠𝑖𝑔𝑛𝑎𝑙  (𝐻𝑧)𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛  𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦  𝑜𝑓  𝑡ℎ𝑒  𝑠𝑝𝑒𝑐𝑡𝑟𝑜𝑚𝑒𝑡𝑒𝑟  (𝑀𝐻𝑧) Equation  5:  Chemical  shift  definition  
By distance downfield it means considering signal at higher frequencies [68]. 
The y-axis, corresponding to signal intensity, is dependent on the number of equivalent 
nuclei in the analyte at a certain chemical shift. Not all atoms can be detected by NMR-
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spectroscopy, only some isotopes generate NMR signals. Among the most common detected 
isotopes are 1H, 13C and 19F.  
The coupling constant (J) is another definition commonly present in NMR-
spectroscopy. The J-coupling gives information about the multiplicity (number of peaks), the 
magnitude and the sign of the coupling. For simple systems like 1H-1H, the multiplicity refers 
to the number of adjacent and magnetically nonequivalent protons connected to the one that 
generates the signal. The splitting occurs because each spin interacts with its neighborhood 
through a mechanism described by the coupling Hamiltonian in Equation 6  ℋ! = 2𝜋𝐽!"𝑰! . 𝑰! Equation  6:  The  coupling  Hamiltonian	  
Where i and j are the nuclear spins and Jij is the scalar coupling constant. This is valid 
only in an isotropic situation. For other situations Jij is not scalar and it is a tensor. A number 
comes usually associated with J, which gives information about the number of chemical bonds 
between the two involved spins.    
The magnitude of J-coupling provides information about the proximity of the coupling 
molecule from the other molecule when referring to 1H-1H coupling. When the interacting 
nuclei are different, the magnitude of J is related to the nuclear magnetic moment of the 
coupling isotopes [69][70][68].      
Nuclear Magnetic Resonance was performed at Institute for Chemistry of the 
Humboldt University of Berlin, AG NMR, by Prof. Dr. Clemens Mügge team. 
Samples were provided lyophilized in a tube to be dissolved in DMSO-d6 later.   
 
2.2.3 FUAc-­‐HSA	  synthesis	  
The procedure followed by us to synthesize FUAc-HSA was adapted from the 
described by Grabarek [12] and was very similar to the recently described process by Koziol et 
al [11], however replacing Bovine Serum Albumin by Human Serum Albumin. The binding 
procedure of FUAc to HSA was the procedure known as EDC/NHS. It is based on the capacity 
of EDC to couple carboxyl groups to primary amines. By adding EDC to a carboxyl group the 
product is an unstable reactive o-acylisourea derivative, which will interact with the amine 
group of proteins. 
NHS works as stabilizing agent for the active ester created by addition of EDC to 
carboxylic molecule and it will increase the efficiency of EDC-mediated coupling reaction 
[12][71]. 
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The amount of reagents used was higher than the quantities referred by Koziol et al 
[11] however the molar concentrations were kept the same as described in the same 
publication. 
A buffer solution (6mL PBS and 6mL water) was previously prepared and afterwards 
300mg of HSA was dissolved in it (25 mg/mL). This mixture was mixed inside a Falcon tube 
in the roller mixer for one hour.  
300mg of FUAc (25 mg/mL) and 350mg of Sodium Chloride (29,17 mg/mL) were 
dissolved in 12 mL of water in a glass container. The pH of this solution was then adjusted to 7 
using 1M NaOH solution and stirring the mixture in a magnetic mixer. 234mg MES (19,5 
mg/mL) were added to the last solution once the pH was adjusted. 
600mg EDC (300 mg/mL) and 900mg NHS (450 mg/mL) were dissolved in 2mL of 
water and immediately poured into the FUAc solution. The ratio between EDC/NHS and 
FUAc solutions should be close to 1:6 and pH should be then close to 5.2. This solution was 
stirred for 20 minutes and after this, pH was again adjusted to a value between 7.2 and 7.5 with 
NaOH 10M solution.  
 The HSA solution was poured into the FUAc solution (keeping a volume ratio of 7:6) 
and was stirred for 2 hours. 
 The following step was the centrifugal filtration, when approximately 10mL were put 
inside the centrifugal filtering (cut-off 30 kDa) tubes at each time, and the centrifugation was 
set for 5000x g at 4ºC, for 15 min, with no break. After centrifugation, the supernatant was 
removed to another tube and 7mL of deionized water were added to the solution left in the 
filter. This washing step was repeated three times and for each centrifugation the supernatant 
was saved and frozen for possible posterior analysis.  
Once all centrifugation steps were complete, the FUAc-HSA solution was carefully 
collected from the filtering tube with a micropipette and transferred to a 50mL Falcon tube. 
FUAc-HSA solution was then frozen at -30°C for 24 hours.  
The last step was lyophilisation, what took place for 24 hours. The yielding substance 
was posteriorly kept at -30°C in a Falcon tube. 
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2.2.4 Matrix-­‐assisted	  Laser	  Desorption/	  Ionization	  Time	  of	  Flight	  (MALDI-­‐TOF)	  
 Matrix-assisted Laser Desorption/ Ionization Time of Flight (MALDI-TOF) is a mass 
spectroscopy technique that uses soft ionization by a short laser pulse, with great utility to 
analyze biological molecules. The principle of this technique is ionization of compounds 
without its fragmentation. The substance to be analyzed is, after ionization, mixed and co-
crystallised with a photoactive organic acid matrix (like dihydroxyacetonephosphate (DHAP), 
for instance) that absorbs energy from laser irradiation. Next step is to put the matrix plus 
analytes in the laser bombardment site and charged analytes will be accelerated into a gas 
phase subjected to an electric field [72]. A scheme of this procedure is shown in Figure 8.  
 
Ions travel in a straight and linear direction to detector, on the opposite end of TOF 
tube. The detector measures particle events as a function of time. Time of flight is proportional 
to the square root of molecule mass to charge ratio (m/z) and has a mass resolution of 0,03%, 
approximately.   
The time of flight t is given as: 
𝑡 = 𝑘 𝑚𝑞   Equation  7:  MALDI-­‐TOF  unit  equation  [73] 
where k is a proportionality constant representing factors related to the instrument 
settings and characteristics. 
MALDI-TOF spectrum for FUAc-HSA was recorded with an Autoflex Speed, Bruker 
equipment (Rheinstetten, Germany) in Linear Positive Mode with dihydroxyacetonephosphate 
(DHAP)-matrix, at Max Planck Institute. We provided samples of HSA and FUAc-HSA 
(approximately 2mg each) and Felix Wojcik performed the procedure.  
 
Figure  8  MALDI-­‐TOF  principle  scheme  [148] 
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2.2.5 CD-­‐Spectroscopy	  
Circular Dichroism-Spectroscopy is a Spectroscopy technique with a great utility in 
drug discovery [74].  
 CD-Spectroscopy determines the stereochemistry of chiral drugs and proteins, 
accessing the absolute configuration of chiral compounds in solution. [74] More specifically, 
circular dichroism (CD) is the difference in the absorption A of left-handed circularly polarised 
light (ALCP) and right-handed circularly polarised light (ARCP), so CD can be expressed as 
ΔA= ALCP ‐ ARCP. It occurs when a molecule contains one or more chiral light-absorbing 
groups. Ellipcity is another concept connected to CD-spectroscopy. When linearly polarised 
light pass through a circular dichroic sample it becomes elliptically polarised. This light is not 
fully circular polarised but has elliptical shape due to the differential absorbance (circular 
dichroism). 
The degree of ellipcity  (θ) is defined as the tangent of the ratio of minor to major 
elliptical axis. 
Molar circular dichroism is a common unit used in literature, calculated by the following 
relation: [𝜃]   =   100𝑥𝜃/(𝐶×𝑙)  Equation  8:  molar  ellipcity  
with C being the analyte in Molar and l the probe cell length in centimetre.  
An important use of CD-Spectroscopy is to access the secondary structure of proteins 
Figure   9:   Standard   CD-­‐Spectroscopy   curves   for  proteins  according  to  its  folding.  [149]  
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and how it can be changed. The signal can be positive or negative depending on whether side-
handed is absorbed in a greater extent. This concept is related to the wave nature of light. As 
above-mentioned, CD-Spectroscopy is widely used to find out secondary structure of proteins, 
mainly secondary elements of proteins like α-helix and β-sheets. Standard spectra for these 
cases are seen in Figure 9 [75][76]. 
The CD-Spectroscopy spectra were recorded with JASKO J-720 Japan (Tokyo, Japan) 
with the following settings: band width 1.0nm, response 1 sec, measurement range 260–
183nm, data pitch 0.1nm, scanning speed 100nm min-1, accumulation 10, cell length 0.1 cm, 
cuvette: quartz). Solutions of 2µM (of HSA and FUAc-HSA) were prepared, with H2O and 10 
x 10-3 M phosphate/ 154 x 10-3 NaF buffer as solvents. The choice of Phosphate/ NaF buffer 
was due to its similarity with physiological solutions.  
CD-Spectroscopy acquisition took place at  the Leibniz-Institut für Molekulare 
Pharmakologie im Forschungsverbund Berlin. Dr. Margitta Dathe kindly provided access to 
equipment and the lab technician, Heike Nikolenko, guided the procedure.  
 
2.2.6 Cell	  culture	  procedures	  
Cell culture methods are performed in accordance to the experience of the work group 
members and following the suppliers’ instructions (Life Technologies for reagents and ATCC 
for cell lines). Cells in culture are maintained in 75 cm2 culture flasks, at 37°C in a controlled 
atmosphere with 5% CO2, with 10 mL of RPMI 1640 GLUTAMAX medium supplemented 
with 10% of FBS plus 1% of PenStrep (MDA-MB-231 and T-47D) and 10mL of EMEM 
supplemented with 0,01mg/ml human recombinant insulin, 10% FBS and 1% PenStrep (for 
MCF-7). Cells are controlled 3 times per week, usually Monday, Wednesday and Friday. 
When checked, if the confluence is between 90 to 100%, cells are passaged to a new flask, if 
not, medium inside the flask is replaced by 10 mL of fresh medium.  
Passaging procedure consists on removing cell medium; wash the cells with 1 mL of 
trypsin to remove remain medium. The following step is to add 2 to 3 mL of trypsin to detach 
the cells. They are incubated with Trypsin for about 12 minutes. Once detached, fresh medium 
is put into the flask (the quantity of medium has to be double the previously added quantity of 
trypsin) and cells are resuspended by repeated pipetting. After the resuspension, cells are 
strained through a cell strain in order to obtain single cell suspension.  
The last step is to seed cells in a new flask, deciding the splitting rate. Usually a rate of 
1:15 is enough for the cells to get completely confluent within a convenient time period.  
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2.2.7 Cell	  counting	  procedure	  
The counting procedure starts by collecting 10µL of cell suspension and filling the 
space between the glass cover and the chamber. As the counting chamber has 2 couting grids 
that can be used independently, one was chosen and the correspondent space filled. Pipette tip 
was placed close the glass cover edge and in the centre of Neubauer chamber. Liquid sample 
should then enter the chamber by capillarity, paying attention to the possible bubble formation, 
in that case this proccedure should be repeated.  
Once the chamber was prepared was placed under the microscope to count the cells. 
As seen in Figure 10, grids are divided in nine biggest squares, five divided in smaller areas 
and, the ones located at chamber corners,  divided in twelve squares. The cells found on the big 
four corner squares were then counted, considereing only those toucing upper and left limits, 
as seen in Figure 10. After counting all cells from the four squares, an average number was 
calculated and concentration was calculated according to Equation 9.  𝑐𝑒𝑙𝑙  𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 = !"#$!%#  !"#$%&  !"  !"#$%&'  !"##$  ×  !""""!"#$%&  !"  !"#$%&!  !"#$%&'('&   Equation  9:  calculation  of  cell  concentration  using  Neubauer  counting  chamber  
 Depending on the following procedure, further dilutions were then calculated [77][78]. 
 
2.2.8 MTT	  assay	  
MTT is one of the most widely used cell viability tests due to its reliability and the 
ease to implementation. The use of a tetrazolium dye was first reported in the early 1980s. It 
was the first homogeneous cell viability assay developed for a 96-well plate format and 
suitable for high throughput screening, which strongly contributed for it to be a widely spread 
assay [79]. 
Figure   10:   Neubauer   counting   chamber.   The   right   image   shows   which   cells   should   be   taken   into  account  considering  its  position  in  the  grid.  [150][151]    
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MTT substrate should be prepared in a physiological solution and incubated with the 
cells, such that viable cells convert MTT to formazan. Dead cells have no ability to convert 
MTT into formazan (Figure 11). Even not being a consensual matter, it is generally accepted 
that NADH is the responsible for most MTT reduction, transferring electrons to MTT. Is also 
supported by cellular studies that MTT reduction is not only associated with mitochondria 
activity but also with cytoplasma and lysosome, endosome and plasma membranes [80].  
After MTT reduction, 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (insoluble 
purple-color product) accumulates inside the cells as well as near the cells surface and in 
culture media. Before reading the absorbance with a spectrophotometer, this insoluble product 
has to be solubilized in order to have a homogeneous solution. Adding a detergent and an 
organic solvent can fulfill this requirements [81][82].  
The interpretation of results is based on the fact that the more metabolic active cells 
are in a well, higher is the absorbance value [83].  
 
This cell viability assay was performed based on previous team experience and 
literature descriptions.  
First, 5000 cells were seeded in each well of a 96 well plate, except the 6 wells 
reserved for the blank control. Cell number was calculated by counting cell number in 
suspension solution with the Neubauer cell counting chamber, as described above.  
Cells were left 24 hours to attach to the culture plates in the incubator with 100 µL of 
media in each well. After the first 24 hours, the media was exchanged for media containing the 
drugs under study and albumin (5-FU, FUAc, FUAc-HSA and HSA). To each column of the 
96 well plates, a solution with different concentration of the tested substances was added; 
being the concentrations used 1, 5, 10, 50, 100 and 500 µM (each concentration was tested 7 
fold and controls 6 fold due to inherent restraints of the culture plate). Concentration of FUAc-
32. CellTiter-Fluor® Technical Bulletin. Online at http://www.promega.com/~/media/Files/Resources/
Protocols/Technical%20Bulletins/101/CellTiter-Fluor%20Cell%20Viability%20Assay
%20Protocol.pdf
33. Caspase-Glo® Technical Bulletin. Online at http://www.promega.com/~/media/Files/Resources/
Protocols/Technical%20Bulletins/101/Caspase-Glo%203%207%20As ay%20Protocol.pdf
34. PubChem BioAssay: http://pubchem.ncbi.nlm.nih.gov/assay/
35. Hall MP, Gruber MG, Hannah RR, Jennens-Clough ML, Wood KV. 1998. Stabilization of firefly
luciferase using directed evolution. In: Bioluminescence and Chemiluminescence—Perspectives
for the 21st Century. Roda A, Pazzagli M, Kricka LJ, Stanley PE (eds.), pp. 392–395. John Wiley
& Sons, Chichester, UK.
36. Auld DS, Zhang Y-A, Southall NT. A basis for reduced chemical library inhibition of firefly
luciferase obtained from directed evolution. J Med Chem 2009;52:1450–1458. [PubMed:
19215089]
37. CellTiter-Glo® Technical Bulletin #288. Online at http://www.pr mega.com/~/media/Fil s/
Resources/Protocols/Technical%20Bulletins/101/Caspase-Glo%203%207%20Assay
%20Protocol.pdf.
38. Riss TL, Moravec RA. Use of multiple assay endpoints to investigate the effects of incubation
time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev Technol
2004;2(1):51–62. [PubMed: 15090210]
Figure 1: Structures of MTT and colored formazan product.
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Figure  11:  MTT  and  Formazan  molecule  [81].  
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HSA was adjusted to have the same concentration of FUAc as it was in the pure FUAc. FUAc-
HSA concentration was calculated according to Equation 10. 𝐹𝑈𝐴𝑐 − 𝐻𝑆𝐴  𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 = !"#$  !"#!$#%&'%("#!"  !"  !"#$  !"#$%&#$'  !!"  !"#  !"#$%&#$  Equation  10:  FUAc-­‐HSA  concentration  calculation  for  experiments  
Once the substances were in contact with cells, a MTT test was performed every 24 
hours until the 96 hours.  
 The first step of MTT assay was to remove the 200µL of medium inside each well, 
wash the well with 100µL of PBS and add the MTT sterile solution to each well (1 mg mL-1 in 
the adequate cell culture media). The plate was then left for 2 hours in the incubator with 
controlled environment (5% CO2 and 37ºC).  
After these 2 hours, MTT solution was removed and 100µL of a solubilization solution 
was added (99.4% DMSO, 0.6% acetic acid and 0,1 g mL-1 SDS). The plate was then agitated 
in the dark (involved in silver foil) for 15 minutes and, finally read in the plate 
spectrophotometer at a wavelength of 570 nm [79]. The spectrophotometer (or ELISA reader) 
software is able to compute the absorbance of each well at 570 nm.  
 
2.2.9 Trypan	  Blue	  exclusion	  assay	  
Trypan Blue is a vital stain used to color dead cells membrane. This can be explained 
due to membrane selective transport characteristic of healthy cells, therefore when a cell is 
viable trypan blue cannot pass through its membrane. A characteristic image of trypan blue 
exclusion in a counting chamber is showed at Figure 12.  
 
Aghdaie MH et al.
Hepat Mon. 2013;13(8):e103974
Figure 4. (left) Low and (right) High Power View of Trypan Blue Stained Cells Show Viable Cells with No Color. Dead Cells are Blue because they are Perme-ated by the Trypan Blue
 Isolation of hepatocytes from diﬀerent sources needs good experience to yield high quality cells with high via-bility to serve enough liver function for cell transplanted patient (4). The first hepatocyte isolation has been in mid-1960s, with two step collagenase perfusion technique, which is now widely used (3). In this technique the liver will be perfused by collagenase through a specific perfu-sion pump by cannula ting of the vessels. Then the cells will go through diﬀerent steps of homogenization and cryopreservation (3). There has been significant progress in cell isolation and viability by several modifications to improve the quality of isolated cells, for example addi-tion of N-acetylcysteine during isolation can improve cell viability especially in steatotic livers (10). Over a period of a year, in Shiraz liver transplant center, there have been more than 300 harvested livers and among these cases, we had the opportunity to isolate hepatocytes from 7 ca-daveric livers that have been rejected from transplanta-tion. Majority of these livers have been rejected because of high fat content. It is worthy to mention that we had 8 other rejected livers which have not been used for cell isolation because of diﬀerent reasons such as technical problems and positive viral markers. As the Table 1 shows, seven mentioned livers were rejected because of high ste-atosis and portal vein thrombosis. After hepatocyte isola-tion there are very important steps to make sure that the isolated cells are suitable for transplantation (4). One of the most important criteria is cell viability (8). The pre-cise amount of hepatocytes to maintain minimal meta-bolic requirement has not been definitely determined (11). There should be cell viability more than 60% and each infusion should be about 10 8 cells (4). The mean cell vi-ability in the isolated hepatocytes in our experience was 71.8% ± 21.7. The reports from UK and France have shown the mean viability of 60 ± 3.6% and 83.4 ± 1.0% respec-tively (12). Another major concern is obtaining cells free 
of any microbial contamination (13). Although there is no standard procedure for bacteriological study in he-patocyte transplantation, bacterial screening should be performed on the organ as it arrives and during the cell isolation procedure. The previous reports of the hepa-tocyte isolations have shown about 30% of contamina-tion by organisms such as staphylococci, Diphtheroid and gram negatives as in our experience (13). All of our techniques of cell isolation have been performed under sterile condition, however, microbial cultures were posi-tive in the first four isolated cases in the initial steps of cell isolation before perfusion of the organ, after consid-ering the sterile transfer of the liver to the isolation lab, after harvesting, the last 3 cases were free of contamina-tion. According to our experience, rejected/unused livers can be a good source of viable hepatocyte which can be used for cell transplantation in diﬀerent situation. It is very important to isolate hepatocytes under GMP (Good manufacturing practice) conditions and also to isolate cells as soon as possible after harvesting of the liver. Both of these conditions need sophisticated equipment and experienced enthusiastic staﬀ. After the hepatocyte iso-lation, the next step is cryopreservation of the isolated cells, because there is severe limitation in the number of donor livers that can be used for hepatocyte isolation (1).Isolated hepatocytes have been used in two conditions:1) Metabolic DiseasesUntil now about 30 children and adults with various metabolic diseases such as Crigler-Najjar disease have re-ceived hepatocytes with acceptable short term recovery (14).2) Acute Liver FailureHepatocyte transplantation can act as a bridge to help the patient survive to receive whole organ transplanta-tion, because the cryopreserved hepatocytes are imme-diately available but liver for transplantation may not be 
Figure  12:  Example  of  a  trypan  blue   ssay,  with  viable  (not  stained  in  blue)  an   dead  cells  (stained  in  blue).  Dead  cells  are  permeable  to  trypan  blue.  [152]  
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For Trypan Blue exclusion assay, cells were seeded in 24 well plates with 8 x 104 cells 
per well (or 1,6 x 105 cells/mL, considering that the seeding volume was 500µL). 
24 hours later, media in the wells was replaced by media containing the drugs under test, 
except for one well were cells were left in normal growing conditions for control (with normal 
culture media). Cells were then incubated for 72 hours. 
After the referred incubation, media in the wells was removed to an eppendorf of 
2,5mL, separately, and cells were trypsinized with 0,5mL Trypsin + EDTA for 5 minutes. 
Once detached, 1mL of culture media was added to inactivate trypsin and the well content was 
transferred to another eppendorf tube. 
From each tube, 50µL were taken and put into another eppendorf tube. 50µL of trypan 
blue was then added. The mixture was pipetted up and down in order mix it.  
Solutions were then checked on a hemocytometer, repeating the counting in 3 grids for 
every solution [84]. 
 
2.2.10 Confocal	  Laser	  Scanning	  Microscopy	  
 The confocal laser microscopy technique provides high-resolution optical images with 
the possibility to depth section select. 3-D images can be obtained by reconstruction made by 
computer of point-by-point acquisition. CLSM makes possible to image interior of opaque 
specimens due to lasers usage. A laser beam passes through an aperture and is focused into a 
volume of the analyzed probe by an objective lens. Reflected and scattered laser light and 
possible fluorescence from probe is then collected by the objective lens. The following step is 
Figure  13:  Confocal  Laser  Scanning  Microscopy  scheme.  [86]  
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the separation by the beam splitter of signal corresponding of excitation from emitted light. 
After crossing the pinhole, light is detected by a photomultiplier, converting light into electric 
signal in order to be processed by a computer. [85][86] 
Cell images from Confocal Laser Scanning Microscopy (CLSM) were obtained to 
assess cells metabolism, what was achieved by the use of Dihydrorhodamine 123 
The fluorogenic probe, DHR-123, is membrane permeable probe, of widely spread 
usage to detect reactive oxygen species (ROS). The referred ROS are generated inside the cell 
during proliferation and differentiation processes [87], therefore its existence in the cell is 
associated with an active cell. DHR-123 has been reported as useful in recognition of active 
cells by fluorescence-detection methods, such as CLSM [88][89].   
For this procedure, five thousand cells were seeded in each well of a 15 µ-Slide 8 well 
Ibidi plate. Cells were seeded with 200µL of media and incubated for 24 hours. Ended this 
period, media was changed and media with drugs was added (200µL). Total incubation time 
with under test drugs was 72 hours. DHR-123 wad added to cells in culture 24 hours before 
microscopy. 
Then, cells were incubated for more 72 hours and, finally, analyzed under the 
microscope.  
The images showed at results chapter were obtained with the confocal laser scanning 
microscope referred in section 3.3.4, which is equipped with 100x oil immersion objective and 
numerical aperture 1.3. Images of the samples were prepared applying excitation of DHR-123 
at 488nm. The fluorescence was recorded using along-pass filter of 505 nm. 
 
2.2.11 4.2.11	  DNA	  extraction	  and	  purification	  
 For DNA extraction from cultured cells the first step was to seed cells in 6 well plates, 
0.5 x 106 cells per well. Seeding volume was 1mL. 24 hours after, media with 5-FU and FUAc 
was added, with the concentration of 500µM. 2mL of solution was added to each well, after 
removing the remaining media inside, and cells were incubated at 37°C for 72 hours.  
 Ended the incubation period, media was completely removed from wells and cells 
were detached by trypsinization with 400µL of trypsin+EDTA.  
 After detaching, cells were resuspended and transferred to 2,5mL eppendorf tubes to 
be centrifuged (7 minutes, 300x g, no break). Supernatant was removed without disturbing the 
cell pellet. 1mL sterile PBS was added to each tube and centrifugation step was repeated more 
2 times in order to remove any traces of incubation media. After centrifugation cell pellet was 
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resuspended in PBS (500µL) and cells were counted to assess the concentration (procedure 
described above). Cell suspensions were then diluted to obtain a concentration of 
approximately 5 x 106 cells per 200µL (recommended concentration and volume for DNA 
extraction kit).  
DNA extraction and purification was executed as described at the kit protocol [90], 
without any modifications.  
 To assess DNA concentration in the final elution the absorbance was checked with 
NanoDrop spectrophotometer.  
 Due to technical problems with the DNA isolation kits, what delayed the process, and 
limited access to NMR spectroscopy, results concerning to 5-FU and FUAc DNA 
incorporation were not available by the submission date of this work. In the case of positive 
results, a scientific publication on the matter will be prepared.    
 
2.2.12 	  DNA	  digestion	  	  
In order to measure 19F-NMR signal of the cells isolated DNA, it had to be degraded in 
smaller nucleotide sequences. For this purpose the endonuclease Deoxyribonuclease I 
(commonly known as DNase I) was used. This enzyme is reported to digest DNA into 
approximately 60% dinucleotides, 25% trinucleotides and oligonucleotides being its smaller 
substrate a trinucleotide. It is know to cut DNA in an almost randomly way, although it seems 
to be cleave preferably purine-pyrimidine sequences. [91] 
Protocol was established by adapting described procedures in literature [92][68]. Thus, 
DNaseI quantity was adjusted to DNA concentration having 2 Units of DNase I per 1µg DNA. 
This mixture was incubated at 37°C for 2 hours. Enzyme was then removed from solution by 
centrifugal filtration.  
 
2.2.13 	  Software	  
 Through this work different software was used, mainly as interface for laboratory 
instruments or data processing.  
Referring to laboratory instruments handling, KC Junior™ from BIO-TEK® was the 
operating software for plate spectrophotometer. NMR spectroscopy equipment ran TopSpin™ 
from Bruker®. 
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 MTT and Trypan Blue data was processed using Microsoft Excel 2011 for Mac and 
statistical analysis was performed with Prism 6® by GraphPad. NMR spectroscopy images 
were prepared with iNMR reader, Mestrelab Research. Reference management was done with 
Mendeley Desktop. 
 
2.2.14 Statistical	  Analysis	  and	  IC50	  
MTT raw data obtained from spectrophotometer results was converted to percentage 
setting average absorption of control wells to hundred percent. From the seven data points 
obtained for each concentration, the two extreme values were excluded (the highest and the 
lowest one). The same procedure was applied to points referring to control. MTT assay was 
repeated three times with each cell line, for each repetition the above-described procedure was 
followed. 
Once percentages were calculated, the results were transferred to GraphPad PRISM. 
Results of all the three repetitions for each cell line were considered. From this data group 
were calculated the mean, standard deviation, IC50 and the chosen non-parametric test to 
assess significance of the results.   
Data was tested for normality with D’Agostino-Pearson omnibus normality test [93] 
which is an embed function of Prism. As data failed to fit a normal distribution, a non-
parametric test was chosen. Assuming to have unpaired data-sets (each data-set refers to 
different concentration and substance), the Mann-Whitney was chosen [94], with two-tailed P-
value and confidence level of 99% (P<0,01).  
Calculation of IC50 for each substance with each of the three cell lines was also 
performed with Prism, choosing an embed model that took logarithm of the concentration and 
the relative percentage of cell activity into account. Values were calculated according to 
Equation 11 (Y and X values being the percentage and concentration, respectively) and setting 
100% value for the situation where drug had no effect on the cells and 0% as maximum effect 
(Figure 14).  
 
𝑌 = 1001 + 10!!!"# !"!"  
 
 
 
Figure   14:   IC50   model   description.   Y-­‐axi  represents  relative  cell  metabolic  activity  and   x-­‐axis   logarithm   of   the   respective  drug  concentration.  [153]	  
Equation  11:  IC50  calculation  [153]  
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Referring to cell counting with trypan blue, data was processed with Microsoft Excel and 
graphics shown in results section were prepared in Prism. As previously done for MTT data, 
control was set to 100% and the remaining results compared to control to obtain cell growth in 
percentage when compared to control. To calculate the standard deviation of each percentage 
values was used the embed standard deviation function of Microsoft Excel. Further analysis of 
these data consisted in IC50 calculation with GraphPad. 
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3 Results	  
In the present chapter will be presented the results obtained through this project.  
The NMR-spectroscopy spectra (13C, 1H and 19F) are presented in sections 3.1.1.1, 
3.1.1.2 and 3.1.1.3. For FUAc-HSA characterization, MALDI-TOF and CD-Spectroscopy 
results are shown on Sections 3.2.1 and 3.2.2, respectively. 
The results obtained from the in vitro tests to assess the compounds cytotoxicity are 
presented in section 3.3.  
Confocal Laser Scanning microscopy obtained for the three cell lines can be found in 
section 3.3.4, the last of this chapter. 
3.1 	  FUAc	  characterization	  
In order to evaluate the success of FUAc synthesis, NMR spectroscopy was performed. 
Spectra obtained from 13C, 1H and 19F-NMR Spectroscopy are shown below. 
3.1.1 NMR	  Spectroscopy	  
For an easier analysis of NMR spectroscopy spectra, the 
chemical structural of FUAc is shown in Figure 15. The substituting 
elements and the chain carbon atoms are highlighted and numbered 
according to its position in the FUAc molecule. For the purpose of a 
simplified writing, carbon and the other substituting atoms are referred by 
these notations (C2, N1, etc) within the next subchapters.  
 
 
3.1.1.1 13C-­‐NMR	  Spectroscopy	  
Below is shown the 13C -NMR spectra. There are six signals; the expected ones for 
FUAc molecule which has six carbon atoms.  
Figure   15:   FUAc   chemical  structure.   Scheme   created  with   MarvinSketch  software  
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C1, C2 and C2’ represent singlets and C4, C5 and C6 doublets.  The Fluorine atom 
connected to C5 is strongly electronegative. This electronegativity in the proximity of a carbon 
atom is in the origin of the double peak at 140,60 and 138,33 ppm. This doublet was assigned 
to C5 because this is a typical signal for F-C coupling: is a doublet, obeying to N+1 rule (can 
be applied since 19F has a spin of ½) and has a large coupling constant. The other two doublets 
are a result of the close position to Fluorine atom as well, both corresponding to J2 couplings. 
 
3.1.1.2 1H-­‐NMR	  Spectroscopy	  of	  FUAc	  
FUAc 1H-NMR spectra shows 5 signals, as seen on Figure 17.  
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Abbildung 13: 13C-NMR-Spektrum von FUAc in DMSO-d6. Auf der x-Achse ist die chemische Verschie-
bung δ [ppm] aufgetragen, die y-Achse zeigt die Signalintensität [a.u.]. Die roten Buchstabe-Zahl-Kombinationen 
geben die Zuordnung des jeweiligen Peaks zum C-Atom im FUAc-Molekül an. Die blauen Zahlen sind die Mess-
werte der chemischen Verschiebung. 
Insgesamt sind sechs Signale (drei Singuletts und drei Dubletts) dargestellt, wovon C1’, C2’ und 
C2 Singuletts und C4, C5 und C6 Dubletts sind. Demnach sind sechs C-Atome in dem Molekül 
vorhanden, wie es für FUAc (C6H5FN2O4) erwartet wurde. 
Das Fluoratom an C5-Position besitzt eine starke Elektronegativität und als Folge davon eine 
große elektronenziehende Wirkung [92]. Dadurch werden sogenannte C-F-Kopplungen hervor-
gerufen, was an den Dubletts bei dem 13C-Spektrum erkennbar ist. Bei dem Dublett (140,60 ppm 
und 138,33 ppm) handelt es sich um eine J1-Kopplung (siehe Abschnitt 2.2.5), die durch die di-
rekte Nachbarschaft eines Kohlenstoffatoms zum Fluoratom hervorgerufen wird. Die weiteren 
zwei Dubletts entsprechen J2-Kopplungen. Sie entstehen, da das substituierte Fluoratom eben-
falls am C4- bzw. am C6-Ringatom elektronenziehenden Einfluss ausübt. 
Die Ergebnisse der 1H-NMR-Spektroskopie und der 13C-NMR-Spektroskopie zeigen, dass die 
Synthese von FUAc aus 5-FU erfolgreich verlaufen ist. Aus 1,73 g (13,3 mmol) 5-FU wurden 
0,745 g (3,96 mmol) FUAc hergestellt. Das entspricht einer Ausbeute von ca. 30 %. 
Figure  3.1-­‐b:  C-­‐NMR  Spectroscopy  spectra  of  FUAc.  X-­‐axis  represents  the  chemical  shift  in  ppm  and  y-­‐axis  the  signal  intensity,  which  has  an  arbitrary  unit.  
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At 13,23 ppm there is a peak corresponding to a carboxylic group in C2’. This 
assignment was due to the presence of two Oxygen atoms, causing deshielding in Hydrogen 
atom and consequently moving the signal to the downfield. The area under the curve of the 
peak is 1, so the peak was generated by one Hydrogen atom.   
 The doublet at 11,93 and 11,91 ppm is likely to correspond to the Hydrogen atom 
connected to N3 considering that it was created only by one Hydrogen atom (Area Under the 
Curve (AUC) is one), therefore this atom is under influence of strong electronegative atoms. 
The proximity of two Oxygen atoms (linked to C2 and C4) is likely to explain this downfield 
position. Additionally, by the N+1 rule [95], it is known that there is no other Hydrogen atom 
in the neighborhood of this one.  
Another doublet appears with peaks at 8,09 and 8,07 ppm. AUC suggests that it 
corresponds to one single Hydrogen atom. Chemical shift to downfield suggests the proximity 
to an electronegative atom.  Comparing J3 coupling constant (6,8Hz) with J4 from the previous 
doublet it is possible to conclude this is larger thus indicating a hydrogen or Fluorine atoms in 
position J3.  
At 4,36 ppm there is a peak with AUC approximate to two, meaning the signal 
corresponds to two Hydrogen atoms. Considering the chemical shift displacement it is 
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von 3,4 [92] und verursachen so die relativ große chemische Verschiebung mit hoher 
Wahrscheinlichkeit. 
 
Abbildung 12: 1H-NMR-Spektrum von FUAc in DMSO-d6. Auf der x-Achse ist die chemische Verschiebung 
δ [ppm] aufgetragen. Auf der y-Achse ist die Signalintensität [a.u.] abgebildet. Die Signale sind den jeweiligen 
chemischen Gruppen des FUAc-Moleküls zugeordnet, die ein H-Atom beinhalten. Die grünen Zahlen unter den 
Signalen und die senkrecht darüber befindlichen grünen Integrale geben den Flächeninhalt unter den Signalen an. 
Der Flächeninhalt eines Signals verhält sich proportional zur Anzahl der H-Atome der jeweiligen chemischen 
Gruppe. Die blau n Zahlen am oberen Rand der Abbildung gebe  d n Wert für die chemische Verschi bung δ 
[ppm] wieder. Für das N3-H-, das C6-H- und das C1’-H2-Signal sind außerdem Vergrößerungen dargestellt. Die 
orange- und pinkfarbigen Buchstaben C, O, N und H zeigen die Zuordnung des Peaks zur jeweiligen Gruppe des 
FUAc-Moleküls (siehe Abbildung 5). 
Des Weiteren wurde ein Dublett bei 11,93 ppm und 11,91 ppm mit einer Signalintensität 
von 1,05 gefunden, was auf ein einzelnes H-Atom hindeutet, das eine starke chemische Ver-
schiebung erfährt. Es müssen sich stark elektronenziehende Atome in der Umgebung befinden. 
Deshalb handelt es sich mit sehr großer Wahrscheinlichkeit um das N3-H, dessen direkte Nach-
barn zwei elektronenziehende C=O-Gruppen (am C2 und am C4) sind. Außerdem verfügt das 
Fluor-Atom (am C5) ebenfalls über eine starke elektronenziehende Wirkung und trägt so zur 
Tieffeldverschiebung bei. Die Aufspaltung in ein Dublett resultiert durch das Fluor-Atom, da es 
C2’-O-O-H N3-H C6-H C1’-H2 
Figure  17:   1H-­‐NMR   spectroscopy  of   FUAc.   X-­‐axis   represents   the   chemical   shift   in   ppm  and  y-­‐axis   the  signal  intensity,  which  has  an  arbitrary  unit.  
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reasonable to conclude that there is a weak electron withdrawer neighbor or it suffers the 
influence of both strong electron-withdrawing and strong electron-donating neighbors. This 
peak was then assigned to Hydrogen atom in C1’-H2 since it is influenced by both the electron-
donator N1 and  C2’-OOH. 
The DMSO-δ6 peak was identified according to information in [96].  
 
3.1.1.3 F-­‐NMR	  Spectroscopy	  of	  FUAc	  
19F-NMR spectra shows one signal, a doublet of a doublet. 
 
 
 
 
 
 
 
 
 
 
 
 
The figure above shows a signal with chemical shift of -170.15 ppm split into four peaks. It 
is a doublet of a doublet that is formed in the following manner. A first doublet occurs by a J3-
coupling with 6,4 Hz (corresponds to the J3-coupling from the 1H-NMR spectroscopy (6.8 Hz) 
and is caused by the hydrogen atom coupled C6. A second doublet results from a J4-coupling 
of 4.7 Hz, the 5.1 Hz corresponds to the J4-coupling from the 1H-NMR and is caused by the 
hydrogen atom coupled N3. The second doublet is a result of subsequent splitting of the first 
doublet.  
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7 Anhang 
7.1 19F-NMR-Spektroskopie von FUAc 
 
Abbildung 34: 19F-NMR-Spektrum von FUAc in DMSO-d6. Auf der x-Achse ist die chemische Verschiebung 
δ [ppm] aufgetragen. Auf der y-Achse ist die Signalintensität [a.u.] abgebildet. Die blauen Zahlen am oberen Rand 
der Abbildung geben den Wert für die chemische Verschiebung δ [ppm] wieder. 
Die Ab ildung zeigt in einzelnes zusammenhänge des Signal mit einer chemischen Verschie-
bung δ von -170,15 ppm. Das Signal ist in vier Peaks aufgespalten. Es handelt ich dabei um ein 
Dublett von einem Dublett, das auf f lgen e Weise entsteht. Ein e stes Dublett tritt d rch eine 
J3-Kopplung mit 6,4 Hz auf, die mit der 3-Ko plung aus der 1 - -Spektroskopie (6,8 Hz) 
kor espondiert und durch das Wasserstoffatom hervorgerufen wird, das am C6-Atom von FUAc 
gebunden ist (siehe Abbildung 5). Ein zweites Dublett resultiert aus einer J4-Kopplung mit 
4,7 Hz, die mit der J4-Kopplung aus der 1H-NMR-Spektroskopie (5,1 Hz) annähernd überein-
stimmt und durch das Wasserstoffatom am N3-Atom von FUAc verursacht wird. Abweichungen 
von 10 % zwischen J-Kopplungs-Wertepaaren liegen in einem akzeptablen Bereich. Das zweite 
Dublett führt also dazu, dass das erste Dublett ein weiteres Mal aufgespalten wird. In der Folge 
entstehen insgesamt vier Peaks, die die erfolgreiche Synthese von FUAc aus 5-FU zeigen. 
Figure  3.1-­‐d:  19F-­‐NMR  Spectra  of  FUAc.  X-­‐axis  represents  the  chemical  shift  in  ppm  and  y-­‐axis  the  signal  intensity,  which  has  an  arbit ary  unit.    
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3.2 FUAc-­‐HSA	  characterization	  
3.2.1 	  MALDI-­‐TOF	  
In order to assess the average number of FUAc molecules bound to each albumin 
particle, a MALDI-TOF analysis was performed.  
 
 
First spectrum (Figure 19) refers to HSA, the second (Figure 20) to the superposition 
of FUAc-HSA and HSA spectra and the third spectrum (Figure 21) shows the peaks 
corresponding to both molecules monoionised.  
Referring to Figure 19, there are two main peaks at 33158,95 and 66332,72 m/z. 
Considering human serum albumin molecular weight provided by manufacturer as 66437 Da 
[97], the peak at 66332,72 m/z is assigned to monoionised HSA [HSA + H]+ . Our results 
indicate thus a molecular weight of 66332,72 Da for the tested HSA.   
The origin of the other peak, at 33158,95 m/z, is discussed in Section 4.1.2.1.   
 
Figure  19:  MALDI-­‐TOF   spectra   of   HSA.   The   two   peaks   corresponding   to  monoionised   HSA   (33158,95  m/z)  and  to  double  ionized  HSA  (66332,72  m/z).  X-­‐axys  unit,  m/z  is  the  mass-­‐to-­‐charge  ratio  which  is  the   common   unit   in   mass   spectroscopy   analysis.   This   unit   is   defined   in   chapter   2.2.4.   Spectra   was  acquired  in  Linear	  Positive	  Mode	  with	  dihydroxyacetonephosphate	  (DHAP)-­‐matrix.      
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Both Figure 20 and Figure 21 show the superposition of HSA and FUAc-HSA spectra. 
In the first figure, all acquired points are visible and the second has a smaller window range, 
confining only the peaks assigned to monoionised molecules. Resembling to the procedure for 
HSA spectra, the origin of other visible peaks will be discussed in section 4.1.2.1. 
Figure   20:   MALDI-­‐TOF   spectra   of   FUAC-­‐HSA   (blue)   and   HSA   (red).   Measuring   conditions   and   unit  definitions  as  described  in  Figure  19.	  
Figure   21:   MALDI-­‐TOF   spectra   of   FUAC-­‐HSA   (blue)   and   HSA   (red).   Measuring   conditions   and   unit  definitions  as  described  described  in  Figure  19.	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Nevertheless, the obtained spectra support a successful FUAc-HSA synthesis since FUAc-
HSA peaks are displaced to the right (higher m/z values) meaning that the analyzed particle 
has higher molecular mass. 
The average number of FUAc molecules bound to each HSA molecule was calculated 
based on MALDI-TOF results, according to the following procedure: 𝑝𝑒𝑎k  𝑓𝑜𝑟  𝐹𝑈𝐴𝑐 − 𝐻𝑆𝐴 −   𝑝𝑒𝑎k  for  𝐻𝑆𝐴 =   FUAc  weight  in  FUAc − HSA        (Equation  12)  
so 69238,58 − 66332,76 = 2905,82  Da    (Equation  13)        
Considering FUAc molecular weight as 188,1 Da [11] 
!"#$,!"  !"!"",!   !"!"#$  !"#$%&#$   = 15,4  FUAc  mol. per  HSA  mol.≈ 15  (Equation  14)    
Therefore, for experimental procedures were considered the result of 15 FUAc 
molecules covalently bound to each HSA molecule.  
 
3.2.2 CD-­‐Spectroscopy	  
HSA and FUAc-HSA molecules conformation was investigated by CD-Spectroscopy. 
Figure 22 shows the spectra for HSA and FUAc-HSA (solved in water and phosphate buffer). 
The unit in y-axis is mean residue ellipcity (MRE), which reports the molar ellipticity for 
individual protein residues. MRE values were calculated according to Equation 15. 
Θ!"# = 𝜃585 Equation  15  
With [θ] defined in Equation 8 and 585 being the number of amino acids in HSA. 
Figure  22  CD-­‐Spectroscopy  spectrum  in  phosphate  buffer.  
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The analysis between HSA and FUAc-HSA CD-spectroscopy spectra can be found in 
section 4.1.2.2 of discussion. The secondary structure of pure HSA and when bound to FUAc 
will be compared in order to investigate possible changes in protein conformation due to the 
coupling process.  
 
3.3 	  Cytotoxicity	  studies	  in	  vitro	  
Data related to in vitro tests is presented in this section. Results are grouped by cell line, 
3.3.1, 3.3.2 and 3.3.3 for T-47D, MDA-MB-231 and MCF-7, respectively. In each of the 
previous cell related subchapters are presented the results of MTT assays and cell counting 
with trypan blue staining.    
 
3.3.1 T-­‐47D	  cell	  line	  
In this subchapter are presented the results obtained for T-47D cell line with MTT 
assays and cell counting.  
 
3.3.1.1 MTT	  
All data in the present subchapter were obtained by processing MTT raw data. 
3.3.1.1.1 Relative	  metabolic	  cell	  activity	  across	  time	  
To illustrate compounds influence on T-47D cells its relative metabolic activity is 
shown on bar charts (Figure 24 to Figure 27) at four time points (24, 48, 72 and 96 hours).    
Figure  23:  CD-­‐Spectroscopy  spectrum  in  water.    
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 The results referring to cells incubated with HSA (Figure 24) show no significant 
inhibition at any time point. Tables with all available data points to create these charts are 
available in Appendix.  
 
FUAc-HSA highest concentration (500µM) is associated with a decreasing metabolic 
activity tendency through the experiment time, with mean value of 80,32% at 24 and 56,42% 
at 96 hours. Besides the 100µM at 96 hours (88,25%), no other concentration has an associated 
percentage of less than 90% relative metabolic cell activity. (Figure 25) 
Figure  25:  MTT  results  relative  to  T-­‐47D  for  the  tested  time  points  and  FUAc-­‐HSA  concentrations.  Each  different  coloured   column   represents  a  different   substance   concentration   and   each   group  of   columns  describes  results  at  the  x-­‐axis  correspondent  time  point.  Y-­‐axis  represent  the  relative  metabolic  activity  of  the  cell  line  compared  to  the  control.  Each  bar  corresponds  to  the  average  of  15  data  points.  
Figure  24:  MTT  results  relative   to  T-­‐47D  for  the   tested  time  points  and     HSA  concentrations.  Each  different   coloured   column   represents   a   different   substance   concentration   and   each   group   of  columns   describes   results   at   the   x-­‐axis   correspondent   time   point.   Y-­‐axis   represent   the   relative  metabolic   activity   of   the   cell   line   compared   to   the   control.   No   significant   diferences   relative   to  control  were  found.  Each  bar  corresponds  to  the  average  of  15  data  points.    
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A strong reduction of metabolic activity – less than 50% compared to control- is 
associated with FUAc highest concentration, from 48 hours time point on, inclusive (Figure 
26). At 96 hours time point, 50µM and 100µM concentrations are also associated with relative 
inhibition of more than 50%. Lower FUAc concentrations (1, 5 and 10 µM) do not exhibit 
strong inhibition. Inhibition associated with the highest concentrations increases with time. 
 
 Metabolic Inhibition associated to 5-FU showed a strong tendency as can be seen in 
Figure 27. At 96 hours time point, only the lowest concentration is not associated with a cell 
Figure   27:  MTT   results   relative   to   T-­‐47D   for   the   tested   time   points   and   5-­‐FU   concentrations.   Each  different  coloured  column  represents  a  different  substance  concentration  and  each  group  of  columns  describes   results   at   the   x-­‐axis   correspondent   time   point.   Y-­‐axis   represent   the   relative   metabolic  activity  of  the  cell  line  compared  to  the  control.  Each  bar  corresponds  to  the  average  of  15  data  points.  
Figure   26:   MTT   results   relative   to   T-­‐47D   for   the   tested   time   points   and   FUAc   concentrations.   Each  different  coloured   column   represents  a  different   substance   concentration   and   each   group  of   columns  describes  results  at  the  x-­‐axis  correspondent  time  point.  Y-­‐axis  represent  the  relative  metabolic  activity  of  the  cell  line  compared  to  the  control.  Each  bar  corresponds  to  the  average  of  15  data  points.  
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metabolic inhibition of more than 50%. Relative Cellular activity decreases with time and 
reaches a value of 1,83% for 500 µM at 96 hours. Comparing to HSA, FUAc-HSA and FUAc 
there is a clear stronger reduction on metabolic activity associated with 5-FU.      
	  
3.3.1.1.2 Comparative	  inhibitory	  activity	  of	  substances	  per	  time	  point	  	  
 Each of the following figures, from Figure 29 to Figure 31, show four box plots 
corresponding to the tested substances. Each group of box plots is related to one time point 
(24, 48, 72 and 96 hours). All calculated p-values can be consulted in  
 Results referring to 24 hours (Figure 29) show significant highest metabolic activity 
for cells incubated with 1, 5, 10 and 500 µM of HSA (P=0,0006; P=0,0015; P=0,0063 and P= 
0,0015). Significant less activity than control is associated with FUAc-HSA highest 
concentration (P< 0,0001) and all 5-FU concentrations except the lowest (5µM: P=0,0005; 
10µM: P<0,0001; 50µM: P<0,0001; 100µM: P<0,0001 and 500µM: P<0,0001).  
Only the highest FUAc concentration could be associated with cell metabolism 
significantly different from control. The Figure 28 refers to 48 hours time point, when HSA 
had no significant influence on cell metabolism and with FUAc-HSA, only the highest 
concentration can be associated with activity reduction (P<0,0001). Like in 24 hours time 
point, 5-FU shows the stronger inhibitory activity with all concentrations being significantly 
different from control, with P< 0,0001. 500µM FUAc is associated with a strong metabolic 
activity reduction (P<0,0001) with 50 and 100 µM concentrations showing weaker influence 
but still statistically different from control (P=0,0017 and P<0,0001, respectively). 
At 72 hours time point, as seen in Figure 30, results keep indicating a high inhibitory 
activity of 5-FU, with all concentrations being significantly different from control (1µM: 
P=0,0052 and the remaining with P< 0,0001). The three highest concentrations of FUAc exert 
significant inhibitory activity (P<0,0001) and, concerning to FUAc-HSA, only the highest one 
shows significant inhibitory effect (P<0,0001). HSA in the concentration of 10µM (P=0,0043) 
and FUAc-HSA with 1, 5 and 10µM (P=0,0092; P=0,0019 and P=0,0084= are significantly 
associated with metabolic activity increase compared to control cells. 
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Figure  28:  MTT  results  for  T-­‐47D  cell  line  after  48  hours.  Control  group  on  orange  on  the  right  position  in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested   compounds   in   the   concentration  referred  on  x-­‐axis.  n.s.   states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart  shows  to  HSA  results,  top-­‐right  to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.      
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure  29:  MTT  results  for  T-­‐47D  cell  line  after  24  hours.  Control  group  on  orange  on  the  right  position  in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested   compounds   in   the   concentration  referred  on  x-­‐axis.  n.s.   states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart  shows  to  HSA  results,  top-­‐right  to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.      
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Results from 96 hours (Figure 31) lead to similar analysis with the previous time point. 
Concerning to 5-FU, the statistical analysis is identical with 72 hours. HSA has no significant 
influence on cell metabolism and only the highest concentration of FUAc-HSA shows 
significant inhibitory activity (P< 0,0001). Referring to FUAc, the three highest concentrations 
and 5µM (P=0,0003) have an apparent inhibitory activity on the cells. 
 
 
 
 
 
 
 
 
 
Figure  30:  MTT  results  for  T-­‐47D  cell  line  after  72  hours.  Control  group  on  orange  on  the  right   position   in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested  compounds  in   the  concentration  referred  on  x-­‐axis.  n.s.   states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart  shows  to  HSA  results,  top-­‐right  to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.      
Results 
 69 
 
 
3.3.1.2 Cell	  counting	  	  
Cell counting after trypan blue staining was performed to confirm the cytotoxic 
activity of 5-FU, FUAc and FUAc-HSA suggested by the MTT assay results. As no significant 
inhibition was registered with lower concentrations with most substances, for this procedure 
were chosen only the three highest concentrations. Dead cells occurred very rarely.  
Comparing results for cells incubated with HSA, cell counting suggests a higher 
inhibition due to HSA presence in media than MTT did (93,81; 87,79; 68,14 against 111,6; 
107;101,8 % for, respectively 50; 100; 500 µM).  
For FUAc-HSA, cell counting suggests as strong associated growth inhibition (71,48; 
49,20 and 27,27 % of control cell number), contrasting once more with MTT results, reporting 
a minimum metabolic activity percentage of 68,680% for 500µM. 
Related to three FUAc concentrations, the calculated relative cell number percentage 
suggests very strong growth inhibition (39,75; 25,49 and 11,90 %), values more closely related 
Figure  31:  MTT  results  for  T-­‐47D  cell  line  after  96  hours.  Control  group  on  orange  on  the  right  position  in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested   compounds   in   the   concentration  referred  on  x-­‐axis.  n.s.   states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart  shows  to  HSA  results,  top-­‐right  to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.      
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to MTT results than the previous. These values were calculated setting control for 100%, 
following the same procedure adopted for MTT data. 
The values calculated for 5-FU were, respectively 25,31, 7,58 and 5,84 %, confirming 
its stronger inhibitory activity when compared with the other tested substances. As happened 
for FUAc, 5-FU relative cell number percentage is more similar to MTT values with standard 
deviation between MTT and cell counting values of 2,333 for 50µM, 11,05 for 100µM and 
0,2645 for 500µM. 
 
3.3.1.3 Half	  maximal	  inhibitory	  concentration	  (IC50)	  
The below-shown IC50 values were calculated with MTT and cell counting results in 
percentage, by means of a non-linear curve fitting.  
                  
Substance 
 
Time (hours) 
5-FU 
(µM, 95% 
confidence interval) 
FUAc 
(µM, 95% 
confidence interval) 
FUAc-HSA 
(µM, 95% 
confidence interval) 
HSA 
(µM, 95% 
confidence interval) 
48 77,77 (29,43 to 205,5) 
407,1 
(225,2 to 735,9) 
873,3 
(422,3 to 1806) − 
72 4,141 (2,696 to 6,361) 
133,7 
(91,91 to 194,5) 
911,4 
(560,5 to 1482) − 
96 1,766 (1,082 to 2,884) 
78,80 
(49,34 to 125,9) 
637,6 
(365,5 to 1112) − Table  5:  Calculated  IC50  for  T-­‐47D  cell  line  considering  the  MTT  assay  results.    
  
Figure   32:   Cell   counting   results   for   T-­‐47D   cell   line.   X-­‐axis   lists   the   tested   compounds   and   its  concentration   and   y-­‐axis   is   relative   to   cell   number   percentage   compared   to   control   cells.   The   y-­‐axis  represents  the  relative  cell  number  in  percentage  compared  to  the  control.  
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Substance 
 
Time (hours) 
5-FU 
(µM, 95% confidence 
interval) 
FUAc 
(µM, 95% confidence 
interval) 
FUAc-HSA 
(µM, 95% 
confidence interval) 
HSA 
(µM, 95% 
confidence 
interval) 
72 27,09  (0,09516 to 7711) 
26,24  
(1,465 to 469,9) 
125,4 
(6,437 to 2444) − Table  6:  Calculated  IC50  for  T-­‐47D  cell  line  considering  the  cell  counting  assay  results.  
 
It was not possible to calculate IC50 values for HSA with this method. The IC50 
values were not calculated for 24 hours data since the data points were disperse and the 
algorithm could not converge properly.  
 The lowest IC50 values were assigned to 5-FU, having also an associated narrow 
confidence interval at 72 and 96 hours time points. 
Both FUAc and FUAc-HSA present considerably higher IC50 values and wider 
confidence intervals.    
 
3.3.2 MDA-­‐MB-­‐231	  cell	  line	  
In this chapter can be found the results corresponding to cytotoxicity in vitro tests with 
MDA-MB-231 cell line.   
 
3.3.2.1 MTT	  
The aim of this MTT subchapter is to present results obtained by processing MTT assay 
raw data. 
  
3.3.2.1.1 Relative	  metabolic	  activity	  across	  time	  
 
Figures from Figure 33 to Figure 36 show bar charts with relative metabolic cell 
activity of MDA-MB-231 cells in culture with the substances under test against four time 
points (24, 48, 72 and 96 hours).  
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By analysis of Figure 33 (referring to HSA), there is no strong percentage increase or 
decreasing tendency, either associated with time or concentration. Some bars suggest an 
increasing in metabolic cell activity, mainly the highest concentration at 24 hours (115,70%) 
and the two lowest concentrations at 96 hours (115,1 and 111,80 %, respectively) nevertheless; 
the control value (100%) is contained in ±SD interval for these points. 
 
 
Figure   34:   MTT   results   relative   to   MDA-­‐MB-­‐231   for   the   tested   time   points   and   FUAc-­‐HSA  concentrations.  Each  different  coloured  column  represents  a  different  substance  concentration  and  each   group   of   columns   describes   results   at   the   x-­‐axis   correspondent   time   point.   The   y-­‐axis  represents   the   relative   cell   metabolic   activity   in   percentage   compared   to   the   control.   Each   bar  corresponds  to  the  average  of  15  data  points.    
Figure   33:   MTT   results   relative   to   MDA-­‐MB-­‐231   for   the   tested   time   points   and   HSA  concentrations.   Each   different   coloured   column   represents   a   different   substance   concentration  and   each   group  of   columns  describes   results   at   the   x-­‐axis   correspondent   time  point.   The   y-­‐axis  represents   the   relative   cell  metabolic   activity   in   percentage   compared   to   the   control.   Each   bar  corresponds  to  the  average  of  15  data  points.    
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The chart in Figure 34 refers to FUAc-HSA. There is a decrement in relative metabolic 
activity associated with the highest FUAc-HSA concentration (500µM) across time, reaching a 
value of 61,87% (±10,45) at 96 hours. Based on graphic analysis, cannot be reported any other 
remarkable bias from the control assigned value. 
 
 The above placed bar graphic (Figure 35) exhibits results relative to FUAc, which can 
be associated with a strong reduction of metabolic cell activity. At 24 hours time point, the 
inhibition was not very pronounced however at 48 hours it is already noticeable a significant 
decreasing associated with the two highest concentrations, reaching 73,13 ± 5,974 % for 
Figure  35:  MTT   results   relative   to  MDA-­‐MB-­‐231   for   the   tested   time   points   and   FUAc   concentrations.  Each   different   coloured   column   represents   a   different   substance   concentration   and   each   group   of  columns  describes  results  at  the  x-­‐axis  correspondent  time  point.  The  y-­‐axis  represents  the  relative  cell  metabolic   activity   in  percentage   compared   to   the   control.   Each  bar   corresponds   to   the  average  of   15  data  points.  
Figure  36:  MTT  results  relative  to  MDA-­‐MB-­‐231  for  the  tested  time  points  and  5-­‐FU  concentrations.  Each  different   coloured   column   represents   a   different   substance   concentration   and   each   group   of   columns  describes  results  at  the  x-­‐axis  correspondent  time  point.  The  y-­‐axis  represents  the  relative  cell  metabolic  activity  in  percentage  compared  to  the  control.  Each  bar  corresponds  to  the  average  of  15  data  points.    
Results 
 74 
100µM and 40,98 ± 4,227 % for 500µM. Relative metabolic activity has a minimum value of 
16,50 ± 5,144 % for 500µM at 96 hours. The three lowest concentrations do not cause a cell 
metabolism inhibition of more than 20%.  
 Making an overall analysis, reduction of metabolic cell activity seems to happen along 
with time and concentration increasing, excepting however results referring for 24 hours.   
The fourth graphic in this section (Figure 36) shows results relative to 5-FU.  Based on 
the above-presented results, 5-FU can be associated with a very strong metabolic activity 
inhibition, reaching a value of 1,838 ± 1,354% for 500µM at 96 hours. AT 72 and 96 hours, all 
concentrations are associated with values of less than 80%. Like in previous results, data for 24 
hours do not show a clear metabolic activity-decreasing tendency due to concentration. From 
48 to 96 hours point there is an obvious concentration and time dependent inhibition.    
 
3.3.2.1.2 Comparative	  inhibitory	  activity	  of	  substances	  per	  time	  point	  	  
The first figure of this section (Figure 37) shows 4 box plots relative to MTT 
results for the four tested substances at 24 hours time point.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure  37:  MTT  results  for  MDA-­‐MB-­‐231  cell  line  after  24  hours.  Control  group  on  orange  on  the  right  position   in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested   compounds   in   the  concentration  referred  on  x-­‐axis.  n.s.  states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart   shows  to  HSA  results,   top-­‐right   to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.      
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 As referred previously about 24 hours time point data, it usually do not lead to 
significant conclusions about substances activity on cells. Analyzing the above-presented 
graphics, there are four data groups differing significantly from control: HSA 500µM, FUAc 
500µM and 5-FU 50 and 500µM.  
HSA 500µM is associated with an increased metabolic cell activity (P=0,0013). The 
remaining three referred data groups are associated with a decreasing in metabolic cell activity, 
however only 5-FU 500µM has a highly significant different value, compared to control 
(FUAc 500µM: P=0,1443; 5-FU 50µM: P=0,0035; 5-FU 500µM: P<0,0001).  
 
Figure 39 shows the graphics for tested substances at 48 hours time point. Referring to HSA, 5 
and 10µM concentrations exert an apparent stimulation on cells metabolism (P=0,0017 and 
P=0,0009, respectively). For FUAc-HSA, only 500µM concentration shows a notorious 
associated lower metabolic activity (P<0,0001). Considering 5-FU data, all concentration 
Figure  38:  MTT  results  for  MDA-­‐MB-­‐231  cell  line  after  48  hours.  Control  group  on  orange  on  the  right  position   in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested   compounds   in   the  concentration  referred  on  x-­‐axis.  n.s.  states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart  shows  to  HSA  results,   top-­‐right   to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.      
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resulted in metabolic activity reduction with high statistic significant difference from control 
(P<0,0001). FUAc is also associated with a sharp cellular metabolism decrease but only for the 
two highest concentrations (P<0,0001) and moderated inhibition with 10µM (P=0,0017). 
 
Figure  39:  MTT  results  for  MDA-­‐MB-­‐231  cell  line  after  72  hours.  Control  group  on  orange  on  the  right  position   in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested   compounds   in   the  concentration  referred  on  x-­‐axis.  n.s.  states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart  shows  to  HSA  results,   top-­‐right   to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.      
Figure  40:  MTT  results  for  MDA-­‐MB-­‐231  cell  line  after  96  hours.  Control  group  on  orange  on  the  right  position   in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested   compounds   in   the  concentration  referred  on  x-­‐axis.  n.s.  states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart   shows  to  HSA  results,   top-­‐right   to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.     
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By the analysis of the 96 hours box plots (Figure 40), can be concluded that none of 
HSA concentrations leads to significant inhibition or stimulation of cellular metabolic. 
Concerning to FUAc-HSA, only the highest concentration is related with sharp metabolic 
activity inhibition (P<0,0001). All 5-FU concentrations led to a strong metabolic activity 
decrease (P<0,0001).  
 
3.3.2.2 Cell	  counting	  
 
The results obtained with cell counting procedure with MDA-MB-231 cell line are 
shown in Figure 41. As previously noted, negligible number of dead cells were found in the 
counting procedure. 
 Analyzing the above bar chart, it is possible to conclude that none of the HSA 
concentrations is associated with a significantly decreased cell number (50µM: 93% ± 8; 
100µM: 99%± 7; 500µM: 101% ± 6). The three chosen FUAc-HSA concentrations show a 
similar effect on cells if compared to control values, with counted cells being circa 80% of the 
ones from control (50µM: 81% ± 4; 100µM: 79% ± 2; 500µM: 77% ± 2). FUAc data suggests 
Figure   41:   Cell   counting   results   for  MDA-­‐MB-­‐231   cell   line.   X-­‐axis   lists   the   tested   compounds   and   its  concentration   and   y-­‐axis   is   relative   to   cell   number   percentage   compared   to   control   cells.   The   y-­‐axis  represents  the  relative  cell  number  in  percentage  compared  to  the  control.    
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that it leads to highest inhibition when compared with the same concentration of HSA and 
FUAc-HSA and lowest if compared to 5-FU, showing a pronounced concentration-dependent 
inhibition (50µM: 77% ± 3; 100µM: 66% ± 4; 500µM: 52% ± 4). A very strong growth 
inhibition associated with 5-FU is suggested by these results, also showing concentration 
dependence (50µM: 21% ± 3; 100µM: 11% ± 2; 500µM: 2% ± 1).    
 
3.3.2.3 Half	  maximal	  inhibitory	  concentration	  (IC50)	  
The table below (Table 7) list IC50 values in µM calculated from MTT data and 
Table 8 shows the IC50 for the substances calculated with the cell counting data.   
                    Substance 
 
Time (hours) 
5-FU 
(µM, 95% 
confidence 
interval) 
FUAc 
(µM, 95% confidence 
interval) 
FUAc-HSA 
(µM, 95% 
confidence interval) 
HSA 
(µM, 95% 
confidence 
interval) 
48 24,21 (19,07 to 30,74) 
337,5 
(274,4 to 415,2) − − 
72 4,034 (3,416 to 4,765) 
78,61 
(63,29 to 97,65) 
1531 
(591,9 to 3963) − 
96 1,489 (1,257 to 1,764) 
45,74 
(39,67 to 52,73) 
766,0 
(486,9 to 1205) − Table  7:  Calculated  IC50  for  MDA-­‐MB-­‐231  cell  line  considering  the  MTT  assay  results.  
  
                   Substance 
 
Time (hours) 
5-FU 
(µM, 95% 
confidence interval) 
FUAc 
(µM, 95% confidence 
interval) 
FUAc-HSA 
(µM, 95% 
confidence 
interval) 
HSA 
(µM, 95% 
confidence 
interval) 
72 15,14 (13,91 to 16,47) 
562,3 
(10,71 to 29523) − − Table  8:  Calculated  IC50  for  MDA-­‐MB-­‐231  cell  line  considering  the  cell  counting  assay  results.  
 
5-FU exhibits relatively low IC50 values with a narrow confidence interval. Concerning 
to FUAc-HSA, the calculated values predict the need of high doses in order to inhibit cell grow 
by 50%. Associated confidence interval is also relatively wider than for the other compounds. 
As suggested by previous results, FUAc trigger a weaker response on cells compared to 5-FU, 
presenting higher IC50 values than 5-FU but lower than FUAc-HSA.    
 
3.3.3 MCF-­‐7	  cell	  line	  
The following sections (from 3.3.3.1 to 3.3.3.3) present results concerning to 
MCF-7 cell line and in vitro cytotoxicity tests. 
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3.3.3.1 MTT	  
Within this section are shown results obtained from MTT assays with MCF-7 
cell line. 
3.3.3.1.1 Relative	  metabolic	  activity	  across	  time	  
The present section comprises four bar charts (from Figure 42 to Figure 45), each 
corresponding to one of the tested compounds.  
 
 
 Based on the above-shown graphic (Figure 42) can be assumed that HSA exerts no 
significant inhibition or stimulation on this cell line. Concentration or time dependent 
metabolic inhibition due to HSA could not be noted.  
   Referring to the second graphic of this chapter, Figure 43, which illustrates MTT 
results for cells incubated with FUAc-HSA, there is a consistent tendency of concentration and 
time-dependent inhibition.  Only one data group, FUAc-HSA in the concentration of 500µM at 
96 hours time point, appears associated with less than 60% relative metabolic activity, the 
highest concentration (50,45% ± 4,53).  
Figure   42:   MTT   results   relative   to   MCF-­‐7   for   the   tested   time   points   and   HSA   concentrations.   Each  different  coloured   column   represents  a  different   substance   concentration   and   each   group  of   columns  describes   results   at   the   x-­‐axis   correspondent   time   point.   The   y-­‐axis   represents   the   relative   cell  metabolic   activity   in  percentage   compared   to   the   control.   Each  bar   corresponds   to   the   average  of   15  data  points.    
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Figure   44:   MTT   results   relative   to   MCF-­‐7   for   the   tested   time   points   and   FUAc   concentrations.   Each  different   coloured   column   represents   a   different   substance   concentration   and   each   group   of   columns  describes  results  at  the  x-­‐axis  correspondent  time  point.  The  y-­‐axis  represents  the  relative  cell  metabolic  activity  in  percentage  compared  to  the  control.  Each  bar  corresponds  to  the  average  of  15  data  points.    
Figure  43:  MTT  results  relative  to  MCF-­‐7  for  the  tested  time  points  and  FUAc-­‐HSA  concentrations.  Each  different   coloured   column   represents   a   different   substance   concentration   and   each   group  of   columns  describes  results  at  the  x-­‐axis  correspondent  time  point.  The  y-­‐axis  represents  the  relative  cell  metabolic  activity  in  percentage  compared  to  the  control.  Each  bar  corresponds  to  the  average  of  15  data  points.    
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 The analysis of FUAc on cell metabolic activity based on the graphic (Figure 44) 
suggests the existence of direct relation between compound concentration and metabolism 
inhibition (at 72 and 96 hours time points). The highest the concentration is, the strongest is the 
associated inhibition. Only at 96 hours time point a relative metabolic activity of less than 60% 
is achieved corresponding to the two highest concentrations (100µM: 53,63% ± 8,998; 500µM: 
48,12% ± 12,24).    
 
 Concerning to the last graphic in this section, Figure 45 that corresponds to results for 
5-FU, there a notorious direct relation between concentration, time and metabolic activity 
percentage. The higher is the concentration and the longer is the incubation period, stronger is 
the inhibition. At 96 hours and with 500µM concentration the correspondent relative 
percentage compared to control of metabolic activity is 12,34% ± 1,898.   
 
1.1.1.1.1 Comparative	  substances	  inhibitory	  activity	  per	  time	  point	  	  
The next four chart groups (from Figure 46 to Figure 49) show box plots relative to 
tested compound at one certain time point. 
Figure   45:   MTT   results   relative   to   MCF-­‐7   for   the   tested   time   points   and   5-­‐FU   concentrations.   Each  different  coloured   column   represents   a   different   substance   concentration   and   each  group  of   columns  describes   results   at   the   x-­‐axis   correspondent   time   point.   The   y-­‐axis   represents   the   relative   cell  metabolic   activity   in  percentage   compared   to   the   control.   Each  bar   corresponds   to   the   average  of   15  data  points.    
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 Above results relative to 24 hours support the fact that 5-FU and FUAc action do not 
lead to a significant difference in cells relative metabolic activity. On the other hand all HSA 
concentrations and the three lowest FUAc-HSA concentrations can be associated with 
metabolic activity stimulation (HSA 1µM: P=0,0008; remaining concentrations: P<0,0001; 
FUAc-HSA 1µM: P<0,0001; FUAc-HSA 5µM: P=0,0018; FUAc-HSA 10µM: P=0,0159). 
  
 
Figure  46:  MTT  results  for  MCF-­‐7  cell  line  after  24  hours.  Control  group  on  orange  on  the  right  position  in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested   compounds   in   the   concentration  referred  on  x-­‐axis.  n.s.   states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart  shows  to  HSA  results,  top-­‐right  to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.      
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The Figure 47 refers to results at 48 hours time point, where stimulating effect of HSA 
and FUAc-HSA is less pronounced, showing both substances statistical significant difference 
from control only for the lowest concentration (HSA 1µM: P= 0,0001; FUAc-HSA 1µM: 
P=0,0044). Also at this time point, FUAc-HSA 500µM is associated with cell metabolism 
inhibition (P=0,0020). Two FUAc concentrations and one from 5-FU are suggested to be 
associated with metabolism stimulation (FUAc 10µM: P<0,0001; FUAc 50µM: P=0,0034; 5-
FU 1µM: P<0,0001). FUAc highest concentration and 5-FU concentrations from 10 to 500µM 
could be associated with cell metabolism inhibition (FUAc 500µM: P=0,0007; 5-FU 10 to 
500µM concentrations: P< 0.0001). 
 The next chart group, shown at Figure 48, refers to 72 hours time point. HSA 10µM 
appears as being metabolic stimulating for cells, although with low statistic significance 
(P=0,0013) and the three highest concentrations of FUAc-HSA exert relative strong metabolic 
inhibition on cells (FUAc-HSA 50µM to 500µM: P<0,0001). All the considered 5-FU 
concentrations can be significantly associated with cell metabolic inhibition (5-FU 1µM to 
500µM: P<0,0001) and the highest FUAc concentrations can be described as considerably 
metabolic inhibitory (FUAc 50µM: P=0,0023; FUAc 100µM and FUAc 500µM: P<0,0001). 
Figure  47:  MTT  results  for  MCF-­‐7  cell  line  after  48  hours.  Control  group  on  orange  on  the  right  position  in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested   compounds   in   the   concentration  referred  on  x-­‐axis.  n.s.   states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart  shows  to  HSA  results,  top-­‐right  to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.      
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The last group of charts in this section, Figure 49, suggests that HSA has no significant 
influence on cell metabolism, considering all the 6 different concentrations. FUAc-HSA is 
linked to relative strong metabolic inhibition with the highest concentrations (50, 100 and 500 
µM) and not so significant with 5µM (FUAc-HSA 5µM: P=0,0044; FUAc-HSA 50 to 500µM: 
P<0,0001). All 5-FU concentrations and FUAc concentrations from 50 to 500µM show 
relatively strong association with cell metabolism inhibition (FUAc 50 to 500 µM: P<0,0001; 
5-FU all concentrations: P<0,0001). 
 
 
 
Figure  48:  MTT  results  for  MCF-­‐7  cell  line  after  72  hours.  Control  group  on  orange  on  the  right  position  in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested   compounds   in   the   concentration  referred  on  x-­‐axis.  n.s.   states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart  shows  to  HSA  results,  top-­‐right  to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.      
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3.3.3.2 Cell	  counting	  
In Figure 50 is shown a bar chart with cell counting results for MCF-7, at 72 hours 
time point. As reported for the other cell lines, dead cells were inexistent or in a very low 
number.   
Analyzing the present results, the HSA shows to have directly connected to 
concentration (HSA 50µM: 113% ± 5; HSA 100µM HSA: 98% ± 5; 500µM: 90% ± 3). FUAc-
HSA is associated with a maximum cell growth inhibition for 500µM (71% ± 5) and weaker 
inhibition for lower concentration (FUAc-HSA 50µM: 88% ± 3; FUAc-HSA 100µM: 78% ± 
2). Concerning to results for FUAc and 5-FU, relative cell growth associated with FUAc 
500µM is similar to the caused by 5-FU 50µM (FUAc 500µM: 48% ± 5; 5-FU 50µM: 45% ± 
10), being the lowest relative cell growth registered for 5-FU 500µM (9% ± 4).  
 
Figure  49:  MTT  results  for  MCF-­‐7  cell  line  after  96  hours.  Control  group  on  orange  on  the  right  position  in   all   above-­‐listed   plots,   the   remaining   boxes   correspond   to   tested   compounds   in   the   concentration  referred  on  x-­‐axis.  n.s.   states  a  P-­‐value  >  0,05;  *  a  P  ≤  0,05;  **  a  P  ≤  0,01;  ***  a  P  ≤  0.001;  ****  a  P  ≤  0,0001,  when  compared  to  control.  Top-­‐left  chart  shows  to  HSA  results,  top-­‐right  to  FUAc-­‐HSA,  bottom-­‐left  to  FUAc  and  bottom-­‐right  to  5-­‐FU.      
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3.3.3.3 Half	  maximal	  inhibitory	  concentration	  (IC50)	  
In Table 9, above-shown, are lists the IC50 values relative to tested substances with 
MCF-7 cell line. .  
Table  9:  Calculated  IC50  for  MCF-­‐7  cell  line  considering  the  MTT  assay  results  
 
                   
Substance 
 
Time (hours) 
5-FU 
(µM, 95% 
confidence interval) 
FUAc 
(µM, 95% 
confidence interval) 
FUAc-HSA 
(µM, 95% 
confidence interval) 
HSA 
(µM, 95% 
confidence interval) 
48 736,6 (523,4 to 1037) − 
3394 
(365 to 31561) − 
72 39,66 (34,88 to 45,08) 
592,3 
(464,8 to 754,7) 
1276 
(548,6 to 2968) − 
96 9,456 (7,996 to 11,18) 
413,8 
(288,2 to 594,1) 
557,7 
(304,3 to 1022) − 
Figure   50:   Cell   counting   results   for   MCF-­‐7   cell   line.   X-­‐axis   lists   the   tested   compounds   and   its  concentration  and  y-­‐axis   is  relative   to  cell   number  percentage  compared   to   control   cells.  The   y-­‐axis  represents  the  relative  cell  number  in  percentage  compared  to  the  control.    
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The algorithm could not converge to a concentration value relative to FUAc at 48 
hours neither for HSA relative to the listed three time points. As previously suggested by the 
other results, 5-FU has the lowest IC50 values and FUAc-HSA the highest. 
	  
                            
Substance 
 
 
Time (hours) 
5-FU 
(µM, 95% confidence 
interval) 
FUAc 
(µM, 95% confidence 
interval) 
FUAc-HSA 
(µM, 95% 
confidence 
interval) 
HSA 
(µM, 95% 
confidence 
interval) 
72 39,03 (4,624 to 329,5) 
401,6 
(0,5046 to 319700) − − Table  10:  Calculated  IC50  for  MCF-­‐7  cell  line  considering  the  cell  counting  assay  results.  
 
3.3.4 Confocal	  Laser	  Scanning	  Microscopy	   	  
In this section are presented confocal laser scanning microscopy images of the three 
cell lines stained with DHR-123. The referred dye is burst sensitive, being visible as green 
fluorescence when a cell is active.   
 
3.3.4.1 T-­‐47D	  cell	  line	  
The Effect of 5-FU and FUAc-HSA on T-47D cells activity can be related with the 
difference in shape and DHR 123 fluorescence seen in Figure 51. A high number of active 
cells can be seen in control (incubated with cell culture media without tested substances). By 
comparison with the other two images, there is a notorious difference either referring to the 
number of cells or the green fluorescence. All visible cells incubated with FUAc-HSA show a 
decreased fluorescence. In the third image, can be seen a cell with very little fluorescence and 
one aggregate with unusual shape and strong uniformly distributed fluorescence. This type of 
fluorescence can be explained by the fact that already dead cells are auto fluorescent.   
Figure  51:  CLSM  images  of  T-­‐47D  cells  after  incubation  of  72  hours.    Picture  on   the   left  corresponds  to  control  cells   incubated  with  DHR  123;  picture   in   the  centre  to  cells  incubated  with  FUAc-­‐HSA  and  DHR  123  and  picture  on  the  right  shows  cells  incubated  with  500µμM  5-­‐FU  and  DHR  123.	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3.3.4.2 MDA-­‐MB-­‐231	  cell	  line	  
 
The inherent conclusions to Figure 52 are similar to the referred ones for Figure 51, a 
decreasing in fluorescence in cells incubated with FUAc-HSA is however not so evident in this 
image.    
 
3.3.4.3 MCF-­‐7	  cell	  line	  
 Pictures of MCF-7 (Figure 53) can be compared with pictures of the two previously 
described cell lines. Fluorescence and number of cells decrease is notorious as well as shape 
modifications on the cells incubated with 5-FU and FUAc-HSA.    
Figure  52  CLSM  images  of  MDA-­‐MB-­‐231  cells  after  incubation  of  72  hours.    Picture  on   the   left  corresponds  to  control  cells   incubated  with  DHR  123;  picture   in   the  centre  to  cells  incubated  with  FUAc-­‐HSA  and  DHR  123  and  picture  on  the  right  shows  cells  incubated  with  500µμM  5-­‐FU  and  DHR  123.	    
Figure  53:  CLSM  images  of  MCF-­‐7  cells  after  incubation  of  72  hours.    Picture  on   the   left  corresponds  to  control  cells   incubated  with  DHR  123;  picture   in   the  centre  to  cells  incubated  with  FUAc-­‐HSA  and  DHR  123  and  picture  on  the  right  shows  cells  incubated  with  500µμM  5-­‐FU  and  DHR  123.	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4 Discussion	  
Cancer is a major health issue worldwide. Treatments for cancer have been contributing to 
prolong life of oncological patients even without complete remission of the tumor, however the 
side effects of the available treatments still represent a heavy burden for patients [98]. Within 
cancer treatments, chemotherapy has played a great highlighted role, being the most 
widespread approach to treat cancer. Around 1940, the world was experiencing early days of 
chemotherapy, with the emergence of nitrogen mustard as an effective treatment for 
lymphoma. From that day on, hundreds of new drugs were developed until the eighties, when 
the discovery of new drugs slowed down and there was a need of changing strategies namely 
by using rat models, creating a panel of human cell lines to test drugs and to boost molecular 
and genetic knowledge of tumors [17]. The last was a starting point for cancer-targeted 
therapies, what was also the base for this work. There was a previous work with FUAc and 
albumin at Institute of Transfusion Medicine, however using bovine albumin instead of human. 
Regarding the achievement of promising results that can be assessed at Koziol et al [11] it was 
decided to try the synthesis and characterization of similar conjugates with human serum 
albumin.  
The aim of this project was to synthesize, characterize and perform in vitro tests with 
FUAc-HSA, a particle consisting of 5-FU acetic acid covalently bound to human serum 
albumin. FUAc-HSA microparticles were expected to overcome 5-FU main drawbacks (fast 
body clearance, low selectivity and severe side effects [99][29]) and came as the next step to 
previous work at Institute of Transfusion Medicine, where bovine serum albumin was used 
instead of the homonymous protein with human origin.     
The followed procedures, as well as the obtained results, will be discussed in this chapter. 
Main technical problems and suggestions for future improvement of this research project will 
be discussed in the last point of this chapter. 
 
4.1 Substances	  synthesis	  and	  characterization	  
4.1.1 	  FUAc	  	  
5-Fluorouracil acetic acid was synthesized according to a procedure adapted from 
Tada et al [8] that was previously described by Koziol et al [11]. To confirm the successful 
synthesis, FUAc was analyzed by NMR spectroscopy. There are 1H and 13C-NMR 
spectroscopy results published however, to the best of our knowledge, there was none 19F-
NMR spectra in published literature. Whenever we registered different results from the ones 
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reported by Tada et al [8] a suggestion for the reason of this difference is made in the 
respective subchapter.    
 
4.1.1.1 1H-­‐NMR	  
As a an adapted version of Tada [8] protocol was followed in this work, a comparison 
between his 1H-NMR results and ours seems pertinent. In Tada’s paper, reported results 
concerning to 1N-NMR were (referring to chemical shift δ): one singlet at 4,40ppm with AUC 
of two, one doublet at 8,09ppm with AUC of one and broad singlet at 11,18ppm with AUC of 
one. Reported peaks at 8,09ppm and 4,40ppm by Tada are comparable to the ones we obtained 
(8,08ppm and 4,36ppm, respectively) but a considerable shift was noted when comparing our 
peak at 11,9ppm and the one reported by Tada at 11,18ppm. Our results show one peak not 
reported by Tada, placed at 13,23ppm. According to our knowledge on FUAc molecule, this 
peak is expected since it corresponds to the carboxyl at C2. Peaks reported by Tada are relative 
to only four hydrogen atoms but FUAc molecule have five.  
 
4.1.1.2 13C-­‐NMR	  
As reported in the results section, we obtained 6 peaks for 13C-NMR analysis of FUAc, 
each peak corresponding to information related to the 6 constituting carbon atoms of the 
molecule. Tada et al [8] reports no results for 13C-NMR analysis and Kim et al [100] reports 
three peaks, with chemical shifts of 49,5ppm, 131ppm and 170ppm and assigned, respectively, 
to C1’, C5 and C2’. Comparing with the results we obtained, it is noticeable the presence of 
three peaks with approximate chemical shifts (48,84ppm; 130,86ppm and 130,52ppm; 
169,43ppm, respectively). As referred in Results section (3.1.1.1) each of the six carbon atoms 
should have a correspondent peak in the spectra, so we are lead to think that Kim et al either 
omitted the remaining peaks or for technical reasons they were not present in spectra. Small 
differences like the ones registered between our obtained results and the reported results in 
previous publications can be explained by different experimental conditions or different NMR 
equipment.   
 
4.1.1.3 19F-­‐NMR	  
To the best of our knowledge, there is not a published 19F-NMR spectroscopy spectra of 
FUAc, therefore a parallel cannot be done. Anyway, based on the analysis presented at section 
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3.1.1.3, it seemed reasonable for us to conclude that the obtained 19F-NMR supports the 
success of FUAc synthesis.  
 
4.1.2 FUAc-­‐HSA	  	  
As referred in section 2.2.3 which is relative to FUAc-HSA synthesis methods, FUAc 
was bonded to HSA molecule using the EDC/NHS method [12][101]. There were other 
options available instead of using water-soluble carbodiimides (EDC) for the coupling of 
carboxylic group with amine, namely diazomethane, diazoacetyl reagents. Our choice fell on 
EDC since it was suitable for organic synthesis, versatile and of common use; therefore it was 
a well-documented substance. NHS played a role in reaction efficiency since it was reported to 
increase it. The last substance is also a reagent for activating carboxyl groups for conjugation 
with protein primary amines [102][103].  
 
4.1.2.1 MALDI-­‐TOF	  
This particular mass spectroscopy technique is suitable for protein detection and 
quantification and described as very sensitive, since it allows the detection of sub-femtomole 
concentrations, it is relatively easy to perform and inexpensive [104] [105].  
The molecular weight obtained by MALDI-TOF analysis for human serum albumin is 
within the accepted range (difference of 200-300 Da), considering the molecular weight value 
given by the product provider [97][106].  
Besides the peak corresponding directly to HSA molecular weight, another peak at 
33158,95 m/z (singular ionization) is visible. This value corresponds to approximately double 
the mass charge of the singular ionization peak. This is a common occurrence in MALDI-TOF 
spectra as the analyte is ionized by a laser and if it gets double charged ([HSA + 2H]2+) its 
kinetic energy through the time of flight tube will be two-fold the one of the mono-ionized 
analyte [107]. 
The amount of FUAc molecules bound to HSA was calculated according to the above-
mentioned theory as well. As HSA, FUAc-HSA has two main peaks in spectra, at 34576,36 
and 69238,58 m/z, being the last one approximately two-fold the first.  
According to the previously referred formula 𝑝𝑒𝑎k  𝑓𝑜𝑟  𝐹𝑈𝐴𝑐 − 𝐻𝑆𝐴 −   𝑝𝑒𝑎k  for  𝐻𝑆𝐴 =   FUAc  weight  in  FUAc − HSA        (Equation 12) the 
number of FUAc molecules by HSA molecule was the difference between the peaks 
corresponding to the two substances. The average number calculated was 15 FUAc per HSA.  
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Albumin particles prepared with a similar technique and described by Dosio et al [108] 
were reported to achieve a loading of 30 paclitaxel molecules per HSA, so it can be technically 
possible to load more FUAc into HSA either using a different coupling technique or adjusting 
the followed coupling procedure. However, it is also described at Dosio et al that HSA does 
not suffer significant change in global charge with up to 10 paclitaxel molecules per HSA so 
according to this, it is possible that higher HSA loading leads to molecule modifications. Frei 
and [20], support that albumin maintain its physiological stability and half-life with loading 
ratio up to 1.4 mole of drug per mole of HSA. Stehle [109] reported that loading ratios close to 
1:1 for MTX-HSA achieved optimal conditions for targeting MTX into tumors in rats. Taheri 
[48] prepared MTX-HSA particles with EDC as crosslinking agent, though this was a process 
similar to ours. In his work, Taheri compared cytotoxicity of MTX-HSA with loading molar 
ratios of 12, 8 and 2 MTX per HSA and the best results were achieved with the conjugate of 
molar ratio 12 (IC50 values, in ng: 14,3; 24,6 and 45,6 corresponding to loading molar ratios 
of 12, 8 and 2 MTX per HSA, respectively).   
Considering the works previously referred and the fact that MTX has a molecular 
weight (454,44 g/mol) much higher than FUAc (188,1 g/mol), we believed only small changes 
to occur in HSA structure. In order to evaluate HSA structure before and after the coupling of 
FUAc we used CD-Spectroscopy. The maintenance of HSA native structure seems to play an 
important role in its cell uptake.     
 
4.1.2.2 CD-­‐Spectroscopy	  
 As referred in the previous subchapter, CD-Spectroscopy was performed to assess 
conformational changes of HSA. This technique was previously chosen for this purpose, 
namely by Tavirani et al [110], Varlan et al [111] and Zsila et al [112].  
The result we obtained was the expected as the probability of FUAc-HSA to behave like 
pure HSA should be higher without significant protein modification due to FUAc coupling. 
Albumin secondary structure was compared with its structure in FUAc-HSA compound. 
Secondary structure of pure HSA and HSA was calculated according to [113] and the obtained 
values were 69,99% α-helix and 9,68% of β-strand for pure HSA and 69,45% α-helix and 
9,71% for FUAc-HSA. Therefore, no significant change in conformation was observed when 
comparing HSA to FUAc-HSA. Figure I of Annex III shows the difference between both CD-
Spectroscopy spectra, where the little difference between them is also notorious. 
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4.2 In	  vitro	  tests	  
In this section will be discussed the obtained results for cytotoxicity tests presented in 
chapter 3.3. 
 
4.2.1 MTT	  	  
4.2.1.1 Cell	  metabolism	  inhibition	  due	  to	  5-­‐FU	  
This anti-metabolite drug is described as having a strong cell inhibition activity, even 
with very low doses. It was previously reported [114] that its activity is related with the time of 
incubation with cells so for incubation of 72 hours with up to 7,7µM an inhibition of 50% of 
the cells was achieved. IC50 values for 22, 72 and 96 hours with HT-29 cells were, 
respectively 13,1µM, 8,1µM and 5,8µM. These values are not very different from the values 
we obtained for MDA-MB-231 and T-47D cell lines.   
Concerning to our results, the highest cell metabolism inhibition was caused by 5-FU, 
as can be confirmed by the results in chapter 3.3. IC50 values obtained from MTT results are 
very low, mainly for 72 and 96 hours time points. At 48 hours time point, differences on IC50 
values referring to the three cell lines were higher, however standard deviation for MTT data is 
also generally higher.  
 It is possible that the presence of phenol red in the culture media influences the cell 
response to 5-FU since T-47D and MCF-7 have estrogen receptors and has been suggested that 
this compound can promote these cells proliferation acting as a estrogen analog [115]. By this 
association, MDA-MB-231 is not supposed to be much affected by phenol red because it is a 
triple negative cell line, so it does not express high levels of estrogen receptors [116]. Results 
obtained in this work are consistent with the previous stated since MDA-MB-231 cell line is 
the one with the lowest IC50 values, followed by T-47D and MCf-7, respectively. The last cell 
line had a slower growing rate when compared to the other two, so a slower response to 5-FU 
is also explainable in this way because its action mechanism affects preferably dividing cells 
[117].   
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4.2.1.2 Cell	  inhibition	  due	  to	  FUAc	  
FUAc exerted a weaker inhibition in all cell lines if compared with 5-FU, with 
remarkably higher values of IC50 for T-47D and MCF-7 at 48 hours time point. Repeating 
what occurred with 5-FU, MCF-7 was the cell line less sensitive to FUAc.  
Considering FUAc chemical structure, the methyl-carboxyl group at N1 in the uracil 
group changes the molecule in a way that makes it no longer a direct pyrimidine analog, 
interrupting the conversion chain from 5-FU to its metabolites. In fact, Luo et al and Chung et 
al state that it is not likely to occur a conversion of pure FUAc into 5-FU [118][10].  
Terminal carboxyl group present in FUAc is responsible for the molecule charged state 
at physiological conditions, slightly more hydrophilic and higher polarity than 5-FU [8][119]. 
Due to these characteristics, FUAc is less likely to penetrate the cell membrane either by the 
non-privileged interaction with the cell membrane or the lack of resemblance with uracil [120].   
 
4.2.1.3 	  Cell	  inhibition	  due	  to	  HSA	  
Regarding the three cell lines used through this work, none of them showed considerable 
reaction to incubation with HSA. At some time points could be considered that it caused a 
slightly increasing cell activity however it is not significative. Data published on this matter is 
contradictory. A previous publication reported MCF-7 and T-47D cell growth stimulation due 
to the presence of HSA in culture media and no influence on MDA-MB-231 [63], however we 
could not register a strong tendency on this subject. Powell at al [40] reported that serum 
albumin inhibits the proliferation of T-47D and MCF-7 cell lines, although it showed no effect 
on MDA-MB-231. Our MTT results had not shown a clear tendency of a cell inhibition caused 
by HSA either. 
An explanation to consider is that HSA concentrations in the performed cell tests were 
kept under typical physiological concentration, reported as being between 30 and 35 g/L blood 
(or, less than 526µM) [35], what is perhaps not enough to reach high concentrations for an 
accentuated response of the cells. Chan et al [121] reported that human serum albumin has its 
characteristic degradation of N-terminal in temperatures around 30ºC. Serum albumin from 
other species, namely bovine, chicken and rabbit were also tested and this degradation could 
not be observed. Since Powell et al described the serum albumin N-terminal as responsible for 
cell growth inhibition and this undergoes a degradation process at temperatures reached during 
our experiments, HSA might had lost its inhibitory activity on the cells with mABP receptor.  
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4.2.1.4 Cell	  inhibition	  due	  to	  FUAc-­‐HSA	  
The synthesized FUAc-HSA particle did not show a strong inhibitory effect in neither of 
the tested cell lines, not achieving an associated inhibition of more than 50% cell metabolism. 
By comparing the results obtained for FUAc-BSA by Koziol et al [11] and the ones presented 
in this work it is possible to conclude that FUAc-HSA shows a weaker inhibition on T-47D 
and MDA-MB-231 cells. An explanation to consider can be the higher loading ratio achieved 
at FUAc-HSA of 15 FUAc molecules per HSA molecule against twelve FUAc molecules per 
BSA at FUAc-BSA. This higher loading ratio can modify HSA structure and slow the uptake 
of the particle by the cell. In previous publication [122] it is referred that BSA has a higher 
binding constant for Uracil than HSA, in a molecular scale, this can lead to an advantageous 
particle conformation for FUAc-BSA when compared to FUAc-HSA when considering the cell 
uptake of the particle. It was already referred in this work that HSA suffer degradation in its N-
terminal at 30ºC or higher temperatures. This domain plays a role in MCF-7 and T-47D cell 
inhibition by HSA. It has also a possible role in the binding reaction of HSA to FUAc [11]. 
Therefore, this specific degradation of HSA, which does not occur on BSA, can explain the 
difference between the results obtained for the two particles. These differences in the protein 
conformation can influence both in the particle synthesis and in cell uptake. 
To the best of our knowledge, there are no previously published results related to in vitro 
cytotoxicity tests with FUAc-HSA. Chung et al [10] reported release of 5-FU from FUAc-
HSA after administration in rabbits and in PBS with degrading enzymes, however there is no 
information about HSA loading ratio. FUAc-HSA was reported to be present in rabbit plasma 
much longer than pure 5-FU (1µg/mL up to 36 hours versus terminal half-life of 8 minutes). 
This prolonged presence in rabbits blood is related to slow release of 5-FU from FUAc-HSA 
particles, since the cleavage might happens either due to enzyme activity or zero-order 
kinetics.  
   The inhibition of cells should be discussed based on the known process for albumin 
cell uptake, described previously in this work. The cellular uptake process of albumin runs 
mainly by endocytosis [39][20] and albumin is subsequently degraded at the endosomes.  
Albumin showed affinity with membrane proteins, namely the gp60 that is reported to 
be present in endothelial cells. This glycoprotein binds to albumin and the endocytic process is 
triggered, leading the formed endosome through the cell to the extravascular space [19][13].  
SPARC is another protein reported to be secreted by some cancer cells to extracellular matrix, 
to which albumin binds to [39][46]. In fact, this was one of the associated facilitators reported 
by Desai et al [13] for inhibitory effect of nab-paclitaxel.  The other protein reported to have 
an influence on albumin effect on the cells was mABP [40].  
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The choice of the three cell lines for our in vitro tests was made mainly based on the 
presence of the last two referred proteins, mABP and SPARC. As so, MCF-7 were described 
as expressing both, T-47D only one (mABP) and MDA-MB-231 none of them [13][40][123]. 
Regarding the previously described hypothesis for uptake of HSA particles, MCF-7 should be 
the most inhibited cells by FUAc-HSA, followed by T-47D and MDA-MB-231 being the less 
affected. In fact, IC50 value for FUAc-HSA on MCF-7 is the lowest when compared to the 
other cell lines but only at 96 hours time point. This result can be in fact supportive of the 
described hypothesis due to this cell line slow growing rate. It was previously referred that 
FUAc and 5-FU took longer to show strong inhibition on MCF-7 than with the other cell lines. 
It should also be noted that IC50 relative to FUAc and FUAc-HSA at 96 hours with MCF-7 are 
more similar between them than in the other cell lines (IC50 FUAc is 413µM and for FUAc-
HSA 557,7 µM). MCF-7 is the cell line exhibiting highest inhibition after incubation with the 
500 µM of FUAc-HSA for 72 and 96 hours, however not registering a wide difference from 
the results obtained for the remaining cell lines this difference is statistically significant at 96 
hours (MDA-MB-231 vs MCF-7: p-value 0,0019; MDA-MB-231 vs T-47D: p-value= 0,0083; 
T-47D vs MCF-7: p-value < 0,0001).  
Based on this evidence, it should be interesting to either add another time point at 120 
hours of incubation or seed more MCF-7 cells when starting the assay because they grow faster 
when get more confluent, in order to better understand the connection of FUAc-HSA action 
and SPARC/mABP. Comparing the other two cell lines, the IC50 values are in accordance 
with the expected and described by Koziol et al since T-47D cell were more inhibited by 
FUAc-HSA at all considered time points.  
Evidences of pure 5-FU release from FUAc-HSA particles were published by Wang et al 
and Chung et al [10][118]. The exact process in how the cleavage occurs is however not clear. 
 
4.2.2 Comparison	  between	  trypan	  blue	  cell	  counting	  and	  MTT	  results	  
Cell counting and MTT results should not be compared directly since they do not assess 
the same exact variables [124]. MTT is reported to assess critical biochemical cell function 
[125] and it has been described as a quantifier of mitochondrial activity. Cell counting assesses 
the number of cells, which depends on cell division, since the results show the relative 
percentage of cells compared to control (control was considered to be cells incubated only with 
adequate cell culture media). The latter procedure has an associated error of approximately 
25% due to miscounting, errors in chamber loading and statistical errors generated by a low 
cell number in counting chamber.  
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Adding trypan blue after incubation was chosen for the screening of dead cells. It is 
described as a compound that takes advantage of affinity for some cell nuclear component and 
enters the cell due to the breakdown of the diffusion barriers in the membranes, possibly 
associated with a molecular rearrangement of the chromatin. A membrane from a healthy cell 
should not be permeable to trypan blue [126]. The number of dead cells was negligible for all 
cell lines and drug concentration, besides for 500µM of 5-FU in T-47D.   
Cell counting results show a tendency similar to MTT: very strong inhibition of cells 
due to 5-FU; relatively weaker inhibition with FUAc, weak inhibition of MDA-MB-231 and 
MCF-7 due to FUAc-HSA (there was a high inhibition of T-47D) and no apparent effect on 
cells linked to HSA, except T-47D. Although, cell counting results show a stronger cell 
inhibition relative to T-47D and MCF-7 than MTT results, by direct comparison of substance 
and concentration effect. However, the difference is not so wide that the differences between 
MTT and cell counting could not be based on the different processes to which the assays 
assess. There are evidences that an increased tumor cell metabolism, namely the production of 
reactive oxygen species (ROS), is not necessarily associated with increased cellular 
proliferation and is dependent on several cell characteristics [127][128].  
Conversion of MTT to formazan occurs in the presence of NADH, NADPH, 
mitochondrial dehydrogenases and free thiol group of cysteine [79][129]. Funk et al described 
an over-estimation of cell activity in MTT results when albumin was added to cell media 
[129], what can be considered by comparing our results from cell counting and MTT.  
The most accentuated differences between MTT and cell counting results were 
registered for T-47D cell line incubated with 500µM HSA and all the three concentrations of 
FUAc-HSA and FUAc. Based on the cellular reduction chain of MTT to formazan, we 
considered the hypothesis that acetate present in FUAc and FUAc-HSA is cleaved and left free 
inside the cells, being posteriorly activated by acetyl-coA synthetase and thus creating acetyl-
coenzyme A (Acetyl-coA) [130]. Acetyl-coA enters the citric-acid cycle, which produces 
NADH (a MTT reductor) so an acceleration of citric cycle can occur due to extra availability 
of acetyl-coA, as previously observed for prostate cancer cells [11][131]. The previously 
referred process can lead to over-availability of NADH, and consequently an over-reduction of 
MTT not merely connected to the cancer cell normal metabolism. 
Another reason for this difference can be the different ways in which the tested drugs 
lead cells to stop or slow its proliferation. Mooney et al [132] reported different apoptic 
mechanisms between MCF-7 and T-47D cell lines, both in timing and in involved cellular 
entities. As so, can be considered that not all cell lines have the same mechanisms leading to its 
apoptosis.   
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Cell counting experiments were not performed with all the concentrations chosen for 
MTT since it is a time consuming procedure and we could not guarantee cell integrity by 
keeping them out of the CO2 during such a long period. This change of incubator had to be 
carried out due to facility constraints. The reduction of the number of concentrations to test 
from six to three was tough seen as the more adequate option. Since MTT assay was performed 
before cell counting, its results were analyzed and the three highest concentrations were chosen 
for cell counting due to the apparent absence of cell metabolism inhibition associated with the 
lowest concentrations. The choice for the 72 hours time point was based on the previous 
experiments with FUAc-BSA, where cell counting was also performed at the same time point, 
and based on MTT results since cell inhibition was already evident. In the ANNEX II the 
standard deviation between MTT and cell counting results can be consulted.    
 
4.2.3 Confocal	  scanning	  laser	  microscopy	  images	  
To support MTT and cell counting results, confocal laser scanning microscopy images 
were obtained to assess cell metabolism and cell anatomy. The obtained images can be seen 
from Figure 51 to Figure 53. Results from CLSM can be related with MTT results since it is 
clear, when comparing images relative to T-47D and MCF-7, a reduced fluorescence inside the 
cells incubated with FUAc-HSA if compared to control cells. Cell shape is also different from 
control cells and more similar to shapes exhibited by cells incubated with 5-FU. Images 
relative to MDA-MB-231 cell line do not exhibit such a difference in fluorescence between 
cells incubated with FUAc-HSA and control however there is a notorious lower cell 
confluence and modifications in shape. Since the referred microscopy images were intended to 
provide a qualitative idea of cell metabolism and anatomy, a further analysis do not seem 
pertinent.  
 
4.3 Critical	  review	  
The most debatable procedures in this work are MTT and cell counting. Both the 
referred methods have a relatively high associated error. Referring to cell counting, associated 
error is between 20 and 30%, mainly due to pipetting, counting and statistical errors [133]. 
MTT in turn have biased results due to modifications in cell metabolism, interaction with 
compounds in culture media (like HSA, for instance) and even due to unequal evaporation 
associated with 96 wells cell culture plates [134][135].  
As aforementioned, MTT results for 24 hours have a large standard deviation. Data 
relative to 48 hours tended to exhibit lower standard deviation, what led us to consider the data 
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relative to 72 and 96 hours more reliable to infer the drug influence on cell culture. One reason 
for such wide spread results mainly at 24 and 48 hours concerning MTT can be the influence 
on cell cycle exerted by trypsin, used for cell passaging [136]. A study performed with MCF-7 
cell line to assess trypsin-induced proteome alteration found that several proteins known to 
regulate cell metabolism, cell growth, mitochondrial electron transportation and cell adhesion 
were down-regulated after trypsinization and proteins that regulate cell apoptosis were up-
regulated [136]. It was previously reported that mitogen-stimulated mouse spleen cells are 
more active in MTT to formazan reduction than resting cells [79]. Therefore, the decreasing 
tendency of standard deviation along the time, which was observed in MTT results, can be 
associated with above-mentioned information. We hypothesized as well that with prolonged 
incubation period cells had time to recover their normal metabolic activity and the influence of 
trypsin was overtaken since it was removed from culture media when the drugs under research 
were added.       
Concerning to cell counting, it proved to be a very useful technique for cell inhibition, 
although very time consuming. In order to have an adequate number of cells to count we had to 
seed them in a twenty-four well plate hence creating different conditions for the cells to grow, 
namely growth and gas-exchange area. The number of cells to seed for each cell line had also 
to be adjusted since they have different growth curves. Even trying our best to create 
conditions as similar as possible as the ones of MTT assay, they were inevitably different. 
Interestingly, previous publication focused on drug resistance related to cell confluence in 
colorectal and it was suggested that the more confluent the cells were, the more they were 
resistant to the drug [137]. This could be a hypothesis for explanation of discrepancies between 
MTT and cell counting results as well since cells were usual less confluent in 24 well plates 
than in the 96 well plates. The 24 well plates were used for cell incubation in cell counting 
procedure and 96 well plates for MTT assay.  
IC50 values were calculated according to cell inhibition for each of the six 
concentrations of each substance used in the MTT assay and for the three concentrations of 
each drug substance in the cell counting experiments. This value was meant to provide a clear 
way to evaluate how strong the cells were inhibitied by a drug.  We considered that it fulfilled 
its purpose, however it could be more significant by adding more drug concentrations, what 
would be interesting for future experiments. The discrepancy registered between IC50 values 
calculated from MTT and cell-counting data can be due to the differences already referred 
between the two assays, to the error associated with both of them or even with the differences 
between the cell lines and how fast they divide react to 5-FU. It should be considered that IC50 
values were calculated using a fitting equation, so the less data points, the less accurate it can 
be. This difference can also be noticed by looking to the confidence intervals associated with 
Discussion 
 100 
IC50 from MTT and cell counting: the ones relative to cell counting are much wider. Referring 
to results for T-47D cell line, the IC50 values obtained for inhibition due to 5-FU vary 
approximate and for FUAc the difference is not very wide (592 µM with MTT data and 413 
µM with cell counting).  
Finally, as mostly performed in vitro tests, the ones performed by us were intended to 
simulate real tumor environment, which were obviously impossible to achieve. Since there was 
a lack of media circulation, it is difficult to predict how different could the results be if taking 
body clearance of the drugs into account. Considering the inherent physiologic theory, it is 
possible to hypothesize an increasing gap between 5-FU/FUAc and FUAc-HSA cell inhibition 
since the latter would be cleared from circulating blood much latter than the first referred 
substances.  
 Incubation of the three cell lines with fluorescence stained HSA was attempted, 
although not successful due to technical issues in the stained protein synthesis. This 
experiment should however take place in the future in order to prove HSA uptake of cultured 
cells, what could give an overview about the hypothesis that HSA uptake by cell is directly 
connected to the presence of mABP and SPARC proteins in each cell line.    
 
4.4 General	  considerations	  and	  major	  issues	  
Motivation for this work came mainly from the previous successful tests described by 
Koziol et al [11], in which bovine serum albumin was used instead of the human homonym 
protein. Based on the previously shown cytotoxic effect with FUAc-BSA, which was chosen 
due to its much lower price compared to HSA, the project was continued by substituting BSA 
with HSA.  
Bovine and human albumins are very similar, sharing approximately 76% of their 
amino-acid sequence, similar secondary structure and net charge, being its main difference the 
fact that BSA contains one tryptophan residue while HSA contains two [138]. A recent study 
[139] supports however that the assumption of similar behavior between HSA and BSA should 
not be made due to different molecular characteristics. Considering the hypothesis of future 
human tests with this particle, BSA should not be used due to documented occurrence of 
allergic reactions [140][141]. 
  Previous work on the FUAc-HSA particle lacked adequate particle characterization 
(HSA loading ratio) and a synthesis protocol description [10]. However they tested the particle 
in vivo and reported the detection of 5-FU in the rabbit’s blood even thirty-six hours after 
injection and 5-FU was detected in the brain by intravenous administration of 5-Fluorouracil 
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acetic acid HSA conjugates. 5-FU could not be detected in the brain by administration of pure 
5-FU and 5-FU acetic acid (FUAc). Therefore, we considered the hypothesis of a similar 
behavior from our FUAc-HSA conjugates, however in a careful way and requiring further 
confirmation.  
In the previous work with FUAc-BSA conjugate, only three drug concentrations were 
chosen for in vitro tests: 100, 300 and 500 µM. As referred in the methods section, the FUAc-
HSA concentration of 500 µM is equivalent to 500 µM of 5-FU. When designing the 
experiments for this project, there was a decision to change the tested concentrations taking 
into consideration works of Takimoto et al. and Furuya et al. [142][143]. They reported 5-FU 
serum concentrations of a maximum of approximately 12 and 10,5µM in humans treated with 
5-FU infusions administered intravenously. Therefore we considered testing lower 
concentrations comparing to the ones previously chosen. Regarding the results, no significative 
cell inhibition was achieved with concentration under 100µM for FUAc-HSA, however 5-FU 
can be associated with strong cell inhibition even in the concentration of 1µM at 96 hours time 
point. These results suggest either that not all 5-FU was released from FUAc-HSA so the 
incubation time should be prolonged or that the drug released is not pure 5-FU so it has not the 
same cytotoxic power as 5-FU. Therefore, in future experiments, could be interesting to add at 
least one more time point (120 hours) in order to have a better overview of FUAc-HSA 
cytotoxicity and how dependent it is on the time of incubation.   
HSA high loading ratio was associated to conformation changes and higher 
accumulation in liver (or other organs with mononuclear phagocytosis system) by Stehle et al 
[18]. When Stehle et al administrated HSA with less MTX bound particles to rats (1:1 ratio), 
they detected more accumulation in tumor (about 14% of total compound administered), as so 
we hypothesized that FUAc-HSA could have a similar pharmacokinetic profile. This could 
lead to differential HSA loading ratios to target either kidney or liver tumors or tumors located 
in another body structures, like breast for instance. A lower molecular weight of FUAc when 
compared to MTX should however be highlighted (188,1 to 454,56 Da [144]) what suggests 
that could be possible to load HSA with more FUAc than MTX molecules and maintain HSA 
native conformation. 
Major issues faced when working in this project were to overtake uneven cell growth in 
cultures at 96 well plates for more than 48 hours and to optimize DNA extraction protocol. For 
approximately one month we had to dispose MTT assays since control cells were not reducing 
MTT after incubation for 48 hours. Plates and media were screened and finally we found that 
the problem seemed to be the way of placing the plates in the incubator. As for each run of 
MTT assay eight 96 well plates were needed, we used to place four of them in a pile, being the 
one corresponding to 24 hours assay on top and the one for 96 hours on the bottom of the pile. 
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After starting to place every plate directly on the incubator shelf the problem was solved. Our 
hypothesis was that placing the plates in such a way blocked airflow for plates on the bottom 
and cells started to die.  
Regarding DNA extraction, the first extraction kit that we tried was apparently not 
effective and the respective protocol was also not very clear, so we decided to try it several 
times by adjusting the number of cultivated cells but this was not successful. This process took 
approximately one month and the first time a new extraction kit was tried (the kit referred in 
material section (2.1), we could obtain DNA from cells incubated with FUAc and 5-FU 
nonetheless was not possible to obtain further results on that experiment before the submission 
of this work. 
   
4.5 Conclusion	  and	  suggestions	  for	  future	  work	  
As a conclusion, it seems reasonable to state that FUAc-HSA effect looks promising, 
however its relation with SPARC expression in cells was not very clear by considering the 
results of this work. Further tests on this conjugate, namely 5-FU release and half-life in blood-
circulation would be of great interest if we take into account results obtained by other groups 
handling particles with similar characteristics to FUAc-HSA. Our results suggest that mABP 
plays a role in FUAc-HSA effect on the cells, perhaps more central than SPARC since the 
difference between results regarding to MDA-MB-231 and T-47D are wider than between T-
47D and MCF-7. The role of SPARC and mABP proteins in cell endocytic uptake appear as an 
interesting subject to be focused on future investigation since it can reveal unknown pathways 
of albumin-bound drugs uptake. 
Incubating the particles in a physiological solution and performing a HPLC analysis 
could assess 5-FU release from particles. In vivo tests would be of great help in order to 
improve the knowledge about the body clearance and stability of FUAc-HSA.  
There could be interesting to find out if our reaction for FUAc-HSA synthesis could be 
adapted in a way that make possible the control of HSA loading ratio. 
Based on the literature research done for this work, we found a lack of papers comparing 
non-tumorigenic cells to tumor cells. It could lift the veil on how selective the particles can be 
to test them with MCF10 cell line, for instance.  
Different cytotoxicity tests might be important before moving to animal tests in order to 
validate the results already obtained. Tests based on substances like calcein and ethidium 
homodimer-1 assess at the same time membrane integrity and esterase activity and 
quantification is made by flow cytometry without the need of washing steps.  
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Considering the current world economy and therefore the unavoidable cost control in 
healthcare, this approach fit in cost reduction at long term. For FUAc-HSA synthesis, the most 
expensive material is HSA, being however not prohibitive. Besides that, all the other 
substances are fairly cheap and the synthesis reaction can be easily reproduced. If FUAc-HSA 
works as the theory predicts and previous preliminary tests suggest, treatment with this particle 
instead of pure 5-FU would prevent oncologic patients from further health issues due to 5-FU 
systemic toxicity. A higher dose of 5-FU could be reached in the vicinity of a tumor, keeping 
its systemic concentration lower. However this represents a mere hypothesis and several years 
of research on this compound will be needed in order to overtake human tests.     
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ANNEX I 
 I 
ANNEX	  I	  
Mann-­‐Whitney	  test	  results	  (p-­‐value)	  –	  MTT	  	  
 
24	  hours	  
T-47D CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,0006 0,1147 0,7591 0,0652 
5µM 0,0015 0,7591 0,1611 0,0005 
10µM 0,0063 0,1289 0,6738 < 0.0001 
50µM 0,0462 0,7810 0,1793 < 0.0001 
100µM 0,0297 0,1989 0,0084 < 0.0001 
500µM 0,0015 < 0.0001 0,0131 < 0.0001 Table  1:  p-­‐values  for  Mann-­‐Whitney  test  of  T-­‐47D  cell  line  MTT  data  at  24  hours    
 
MDA-MB-231 CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,6739 0,3637 0,9716 0,5452 
5µM 0,6326 0,9149 0,3714 0,1813 
10µM 0,9149 0,2795 0,3870 0,0609 
50µM 0,6739 0,0570 0,4276 0,0035 
100µM 0,9148 0,0652 0,8698 0,0759 
500µM 0,0013 0,1443 0,0063 < 0.0001 Table  2:  p-­‐values  for  Mann-­‐Whitney  test  of  MDA-­‐MB-­‐231  cell  line  MTT  data  at  24  hours    
 
MCF-7 CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,0008 < 0.0001 0,4800 0,0606 
5µM < 0.0001 0,0018 0,8655 0,1439 
10µM < 0.0001 0,0159 0,1063 0,3424 
50µM < 0.0001 0,2399 0,2257 0,7346 
100µM < 0.0001 0,8655 > 0.9999 0,1422 
500µM < 0.0001 0,2548 0,3564 0,1061 Table  3:  p-­‐values  for  Mann-­‐Whitney  test  of  MCF-­‐7  cell  line  MTT  data  at  24  hours    
 
 
ANNEX I 
 II 
48	  hours	  
 
T-47D CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,0697 0,8810 0,1081 < 0.0001 
5µM 0,0610 0,5346 0,8474 < 0.0001 
10µM 0,0156 0,4318 0,8473 < 0.0001 
50µM 0,0479 0,9602 0,0017 < 0.0001 
100µM 0,0792 0,5730 < 0.0001 < 0.0001 
500µM 0,3870 < 0.0001 < 0.0001 < 0.0001 Table  4:  p-­‐values  for  Mann-­‐Whitney  test  of  T-­‐47D  cell  line  MTT  data  at  48  hours    
 
MDA-MB-231 CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,1217 0,9829 < 0.0001 0,6327 
5µM 0,1216 0,0652 0,0003 < 0.0001 
10µM 0,1148 0,0065 0,0172 < 0.0001 
50µM 0,0860 0,0286 0,0846 < 0.0001 
100µM 0,3060 0,0845 < 0.0001 < 0.0001 
500µM 0,2546 0,0532 < 0.0001 < 0.0001 Table  5:  p-­‐values  for  Mann-­‐Whitney  test  of  MDA-­‐MB-­‐231  cell  line  MTT  data  at  48  hours    
 
MCF-7 CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,0001 0,0044 0,9502 < 0.0001 
5µM 0,9219 0,6750 0,0103 0,3029 
10µM 0,3758 0,5737 < 0.0001 < 0.0001 
50µM 0,6235 0,0717 0,0034 < 0.0001 
100µM 0,0607 0,0323 0,0658 < 0.0001 
500µM 0,0115 0,0020 0,0007 < 0.0001 Table  6:  p-­‐values  for  Mann-­‐Whitney  test  of  MCF-­‐7  cell  line  MTT  data  at  48  hours    
 
 
 
 
ANNEX I 
 III 
72	  hours	  
 
T-47D CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,1747 0,0092 0,0121 0,0052 
5µM 0,0276 0,0019 0,9149 < 0.0001 
10µM 0,0043 0,0084 0,6739 < 0.0001 
50µM 0,2607 0,7375 < 0.0001 < 0.0001 
100µM 0,9376 0,0120 < 0.0001 < 0.0001 
500µM 0,6533 < 0.0001 < 0.0001 < 0.0001 Table  7:  p-­‐values  for  Mann-­‐Whitney  test  of  T-­‐47D  cell  line  MTT  data  at  72  hours    
 
MDA-MB-231 CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,0114 0,1499 0,9579 < 0.0001 
5µM 0,0017 0,2335 0,0285 < 0.0001 
10µM 0,0009 0,3606 0,0017 < 0.0001 
50µM 0,7212 0,0850 < 0.0001 < 0.0001 
100µM 0,5277 0,0850 < 0.0001 < 0.0001 
500µM 0,1884 < 0.0001 < 0.0001 < 0.0001 Table  8:  p-­‐values  for  Mann-­‐Whitney  test  of  MDA-­‐MB-­‐231  cell  line  MTT  data  at  72  hours    
 
MCF-7 CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,1061 0,8094 0,9219 < 0.0001 
5µM 0,3378 0,7546 0,3953 < 0.0001 
10µM 0,0013 > 0.9999 0,0776 < 0.0001 
50µM 0,4150 < 0.0001 0,0023 < 0.0001 
100µM 0,8097 < 0.0001 < 0.0001 < 0.0001 
500µM 0,7549 < 0.0001 < 0.0001 < 0.0001 Table  9:  p-­‐values  for  Mann-­‐Whitney  test  of  MCF-­‐7  cell  line  MTT  data  at  72  hours    
 
 
 
 
ANNEX I 
 IV 
96	  hours	  
 
T-47D CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,3773 0,3973 0,0237 < 0.0001 
5µM 0,6738 0,8641 0,0003 < 0.0001 
10µM 0,6491 0,6905 0,5695 < 0.0001 
50µM 0,3950 0,6696 < 0.0001 < 0.0001 
100µM 0,3546 0,5314 < 0.0001 < 0.0001 
500µM 0,8489 < 0.0001 < 0.0001 < 0.0001 Table  10:  p-­‐values  for  Mann-­‐Whitney  test  of  T-­‐47D  cell  line  MTT  data  at  96  hours    
 
MDA-MB-231 CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,0062 0,3447 0,0381 < 0.0001 
5µM 0,0485 0,5156 0,0009 < 0.0001 
10µM 0,2613 0,2884 < 0.0001 < 0.0001 
50µM 0,5230 0,5230 < 0.0001 < 0.0001 
100µM 0,0794 0,1412 < 0.0001 < 0.0001 
500µM 0,0231 < 0.0001 < 0.0001 < 0.0001 Table  11:  p-­‐values  for  Mann-­‐Whitney  test  of  MDA-­‐MB-­‐231  cell  line  MTT  data  at  96  hours    
 
MCF-7 CTL vs HSA CTL vs FUAc-HSA CTL vs FUAc CTL vs 5-FU 
1µM 0,6490 0,9501 0,8653 < 0.0001 
5µM 0,3202 0,0044 0,9785 < 0.0001 
10µM 0,0390 0,0177 0,1232 < 0.0001 
50µM 0,1422 < 0.0001 < 0.0001 < 0.0001 
100µM 0,7013 < 0.0001 < 0.0001 < 0.0001 
500µM 0,1989 < 0.0001 < 0.0001 < 0.0001 Table  12:  p-­‐values  for  Mann-­‐Whitney  test  of  MCF-­‐7  cell  line  MTT  data  at  96  hours    
 
 
ANNEX II 
 I 
ANNEX	  II	  
Standard deviation of MTT and cell counting values for the three cell lines at 72 hours time 
point 
 
T-47D HSA FUAc-HSA FUAc 5-FU 
50µM 12,73 19,80 17,68 2,121 
100µM 14,14 29,70 19,09 11,31 
500µM 23,33 28,99 12,73 0,0 Table  1:  Standard  deviation  between  MTT  and  cell  counting  percentage  values  relative  to  T-­‐47D  cell   line  at  the  72  hours  time  point  
 
MDA-MB-
231 HSA FUAc-HSA FUAc 5-FU 
50µM 11,31 10,61 13,44 0,7071 
100µM 4,950 7,778 16,97 4,243 
500µM 7,778 3,536 21,92 2,121 Table  2:  Standard  deviation  between  MTT  and  cell  counting  percentage  values  relative  to  MDA-­‐MB-­‐231  cell  line  at  the  72  hours  time  point  
 
MCF-7 HSA FUAc-HSA FUAc 5-FU 
50µM 9,899 5,657 1,414 1,414 
100µM 1,414 0,7071 9,899 12,02 
500µM 6,364 7,071 3,536 12,02 Table  3:  Standard  deviation  between  MTT  and  cell  counting  percentage  values  relative  to  MCF-­‐7cell   line  at  the  72  hours  time  point  
ANNEX III 
 I 
ANNEX	  III	  
Subtraction of HSA from FUAc-HSA CD-spectroscopy spectra. 
 
 
 
 
Figure  1  :  Subtraction  of  HSA  from  FUAc-­‐HSA  CD-­‐spectroscopy  spectra    
